Dasatinib

For research use only. Not for use in humans.

目录号：S1021 别名： BMS-354825 中文名称：达沙替尼

CAS No. 302962-49-8

Dasatinib (BMS-354825) 是一种新型有效的多靶点抑制剂，作用于Abl、Src和 c-Kit，在无细胞试验中IC50分别为 <1 nM、0.8 nM 和 79 nM。Dasatinib 可诱导自噬和凋亡并具有抗肿瘤的活性。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 1142.64	现货
25mg	RMB 1224.97	现货
100mg	RMB 3039.93	现货
250mg	RMB 5487.3	现货
500mg	RMB 6691.23	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的Dasatinib发表文献386篇：

Nature, 2020, 10.1038/s41586-020-2884-6

PubMed: 33149299 ( click the link to review the publication )

Science, 2020, 370(6513)eabc2754

PubMed: 33004676 ( click the link to review the publication )

Cell, 2020, 182(3):685-712.e19

PubMed: 32645325 ( click the link to review the publication )

Cell Stem Cell, 2020, 10;S1934-5909(20)30144-2

PubMed: 32413332 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Nat Immunol, 2018, 19(6):561-570

PubMed: 29777213 ( click the link to review the publication )

Nature, 2017, 543(7647):728-732

PubMed: 28321130 ( click the link to review the publication )

Nat Med, 2017, 23(3):291-300

PubMed: 28191885 ( click the link to review the publication )

Nat Med, 2017, 23(12):1424-1435

PubMed: 29131160 ( click the link to review the publication )

Cancer Discov, 2016, 6(7):727-39

PubMed: 27231123 ( click the link to review the publication )

Cancer Cell, 2016, 29(4):563-573

PubMed: 27070703 ( click the link to review the publication )

Nat Genet, 2014, 46(2):166-70

PubMed: 24413734 ( click the link to review the publication )

Cell, 2012, 21;151(7):1457-73.

PubMed: 23245941 ( click the link to review the publication )

Cell Stem Cell, 2012, 10(2):210-7

PubMed: 22305570 ( click the link to review the publication )

Cancer Discov, 2011, 1(7):608-25

PubMed: 22586683 ( click the link to review the publication )

Drug Metab Dispos, 2021, 49(1):53-61

PubMed: 33148688 ( click the link to review the publication )

Blood, 2020, 8 pii: blood

PubMed: 32270193 ( click the link to review the publication )

Cell Res, 2020, 27;1-16

PubMed: 32341413 ( click the link to review the publication )

Mol Cell, 2020, 7;S1097-2765(20)30269-0

PubMed: 32416067 ( click the link to review the publication )

J Clin Invest, 2020, 1;130(4):1879-1895

PubMed: 31874105 ( click the link to review the publication )

Nat Commun, 2020, 11(1):5842

PubMed: 33203880 ( click the link to review the publication )

Sci Adv, 2020, 6(34):eaba8968

PubMed: 32937365 ( click the link to review the publication )

Leukemia, 2020, 14

PubMed: 32409689 ( click the link to review the publication )
Neuro Oncol, 2020, 15;22(4):493-504

PubMed: 31883012 ( click the link to review the publication )

Genome Med, 2020, 18;12(1):17

PubMed: 32070411 ( click the link to review the publication )

Cancer Res, 2020, 30 pii: canres

PubMed: 32354737 ( click the link to review the publication )

Cell Rep, 2020, 31(12):107800

PubMed: 32579927 ( click the link to review the publication )

Cell Rep, 2020, 24;30(12):3951-3963 e4

PubMed: 32209458 ( click the link to review the publication )

Cell Rep, 2020, 30(3):793-806

PubMed: 31968254 ( click the link to review the publication )

J Hematol Oncol, 2020, 13(1):80

PubMed: 32552902 ( click the link to review the publication )

Oncogene, 2020, 39(20):3980-3996

PubMed: 32238881 ( click the link to review the publication )

Oncogene, 2020, 39(2):308-321

PubMed: 31477830 ( click the link to review the publication )

Oncogene, 2020, 10.1038/s41388-020-1255-y

PubMed: 32157217 ( click the link to review the publication )

Oncogene, 2020, 39(20):4045-4060

PubMed: 32214198 ( click the link to review the publication )

Cancers (Basel), 2020, 12(11)E3172

PubMed: 33126775 ( click the link to review the publication )

Cancers (Basel), 2020, 12(9)E2586

PubMed: 32927828 ( click the link to review the publication )

Cancers (Basel), 2020, 27;12(5)pii: E1087

PubMed: 32349331 ( click the link to review the publication )

Cancers (Basel), 2020, 25;12(5)

PubMed: 32344828 ( click the link to review the publication )

Cancers (Basel), 2020, 13;12(2) pii: E436

PubMed: 32069833 ( click the link to review the publication )

Cancers (Basel), 2020, 12(10)E2730

PubMed: 32977582 ( click the link to review the publication )

Cancers (Basel), 2020, 31;12(4) pii: E841

PubMed: 32244515 ( click the link to review the publication )

Cancers (Basel), 2020, 26;12(4)

PubMed: 32224911 ( click the link to review the publication )

Cancers (Basel), 2020, 12(12)E3869

PubMed: 33371412 ( click the link to review the publication )

PLoS Pathog, 2020, 16;16(3):e1008341

PubMed: 32176725 ( click the link to review the publication )

Breast Cancer Res, 2020, 15;22(1):37

PubMed: 32295603 ( click the link to review the publication )

Cell Death Discov, 2020, 15;6:36

PubMed: 32435511 ( click the link to review the publication )

Br J Cancer, 2020, 10.1038/s41416-020-0952-1

PubMed: 32572172 ( click the link to review the publication )
FASEB J, 2020, 34(3):3773-3791

PubMed: 31945226 ( click the link to review the publication )

Mol Cancer Ther, 2020, molcanther.1160.2019

PubMed: 33323457 ( click the link to review the publication )

Br J Haematol, 2020, 10.1111/bjh.17139

PubMed: 33216963 ( click the link to review the publication )

Stem Cell Res Ther, 2020, 11(1):270

PubMed: 32631432 ( click the link to review the publication )

Transl Lung Cancer Res, 2020, 9(5):1810-1821

PubMed: 33209603 ( click the link to review the publication )

Mol Cancer Res, 2020, 10.1158/1541-7786.MCR-19-0669

PubMed: 32238439 ( click the link to review the publication )

Microb Cell Fact, 2020, 20;19(1):74

PubMed: 32197603 ( click the link to review the publication )

J Cell Mol Med, 2020, 10.1111/jcmm.14980

PubMed: 32032474 ( click the link to review the publication )

Biochem Pharmacol, 2020, 30;177:113941

PubMed: 32240650 ( click the link to review the publication )

Biochem Pharmacol, 2020, S0006-2952(20)30604-3

PubMed: 33333074 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(23)E9276

PubMed: 33291786 ( click the link to review the publication )

Int J Mol Sci, 2020, 18;21(8):2825

PubMed: 32325639 ( click the link to review the publication )

Sci Rep, 2020, 10(1):20343

PubMed: 33230163 ( click the link to review the publication )

Sci Rep, 2020, 10(1):16616

PubMed: 33024173 ( click the link to review the publication )

Sci Rep, 2020, 6;10(1):4211

PubMed: 32144278 ( click the link to review the publication )

Am J Pathol, 2020, S0002-9440(20)30550-2

PubMed: 33307038 ( click the link to review the publication )

J Biol Chem, 2020, jbc.RA120.015489

PubMed: 33037073 ( click the link to review the publication )

Cancer Cell Int, 2020, 19;20:58

PubMed: 32099531 ( click the link to review the publication )

Breast Cancer Res Treat, 2020, 179(2):337-347

PubMed: 31655920 ( click the link to review the publication )

Cell Signal, 2020, 70:109574

PubMed: 32084531 ( click the link to review the publication )

Molecules, 2020, 8;25(9) pii: E2220

PubMed: 32397330 ( click the link to review the publication )

Oncol Rep, 2020, 44(6):2581-2594

PubMed: 33125153 ( click the link to review the publication )

J Pharm Biomed Anal, 2020, 195:113864

PubMed: 33387839 ( click the link to review the publication )

Biomol Ther (Seoul), 2020, 9

PubMed: 32268657 ( click the link to review the publication )
SLAS Discov, 2020, 19;2472555220915851

PubMed: 32425084 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00425-8

PubMed: 32886306 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00420-z

PubMed: 32870449 ( click the link to review the publication )

Biochim Biophys Acta Gen Subj, 2020, 1864(4):129507

PubMed: 31881245 ( click the link to review the publication )

Breast Cancer Res, 2020, 22(1):84

PubMed: 32771039 ( click the link to review the publication )

Blood Adv, 2020, 4(24):6106-6116

PubMed: 33351104 ( click the link to review the publication )

bioRxiv, 2020, 2020/9/20.4.7.30734

PubMed: 32511305 ( click the link to review the publication )

Commun Biol, 2020, 3(1):18

PubMed: 31925328 ( click the link to review the publication )

J Exp Med, 2020, 217(2)

PubMed: 31704808 ( click the link to review the publication )

Oncol Lett, 2020, 20(1):145-154

PubMed: 32565942 ( click the link to review the publication )

J Clin Invest, 2020, 133310

PubMed: 32603316 ( click the link to review the publication )

Genome Biol, 2020, 21(1):174

PubMed: 32669109 ( click the link to review the publication )

Cancer Cell, 2020, 38(6):872-890.e6

PubMed: 33217342 ( click the link to review the publication )

Hemasphere, 2020, 4(6):e497

PubMed: 33196013 ( click the link to review the publication )

Signal Transduct Target Ther, 2020, 5(1):139

PubMed: 32792487 ( click the link to review the publication )

Neoplasia, 2020, 22(10):470-483

PubMed: 32818841 ( click the link to review the publication )

EMBO Mol Med, 2020, 12(12):e12391

PubMed: 33231937 ( click the link to review the publication )

Nat Commun, 2020, 11(1):3416

PubMed: 32651372 ( click the link to review the publication )

Cells, 2020, 9(8):E1807

PubMed: 32751526 ( click the link to review the publication )

Cells, 2020, 9(2)

PubMed: 32102381 ( click the link to review the publication )

Nat Cell Biol, 2019, 21(6):778-790

PubMed: 31160710 ( click the link to review the publication )

Am J Respir Crit Care Med, 2019, 101164/rccm201902-0451OC

PubMed: 31738079 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2556

PubMed: 31186408 ( click the link to review the publication )

Nat Commun, 2019, 10(1):1515

PubMed: 30944303 ( click the link to review the publication )
Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-19-2309

PubMed: 31857430 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(16):5038-5048

PubMed: 31182436 ( click the link to review the publication )

Cancer Res, 2019, 79(1):209-219

PubMed: 30389701 ( click the link to review the publication )

Haematologica, 2019, 10.3324/haematol.2019.215939

PubMed: 31289206 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-19-1104

PubMed: 31585938 ( click the link to review the publication )

Mol Syst Biol, 2019, 15(3):e8323

PubMed: 30858180 ( click the link to review the publication )

Mol Syst Biol, 2019, 15(8):e8849

PubMed: 31464373 ( click the link to review the publication )

Cancer Res, 2019, 79(13):3306-3319

PubMed: 31101761 ( click the link to review the publication )

Theranostics, 2019, 9(7):1952-1964

PubMed: 31037149 ( click the link to review the publication )

Cell Rep, 2019, 28(9):2331-2344

PubMed: 31461650 ( click the link to review the publication )

Thyroid, 2019, 29(3):395-404

PubMed: 30724135 ( click the link to review the publication )

Oncogene, 2019, 38(29):5805-5816

PubMed: 31235784 ( click the link to review the publication )

Oncogene, 2019, 38(12):2135-2150

PubMed: 30459358 ( click the link to review the publication )

Stem Cell Reports, 2019, 10.1016/j.stemcr.2019.08.005

PubMed: 31522974 ( click the link to review the publication )

Cancers (Basel), 2019, 11(12)E1945

PubMed: 31817360 ( click the link to review the publication )

Br J Cancer, 2019, 121(7):567-577

PubMed: 31474759 ( click the link to review the publication )

J Clin Med, 2019, 8(8)

PubMed: 31382448 ( click the link to review the publication )

J Clin Med, 2019, 8(4)E455

PubMed: 30987403 ( click the link to review the publication )

Cancer Discov, 2019, 9(6):756-777

PubMed: 30862724 ( click the link to review the publication )

Mol Cancer Ther, 2019, 10.1158/1535-7163.MCT-19-0449

PubMed: 31744897 ( click the link to review the publication )

Pharmacol Res, 2019, 147:104357

PubMed: 31356863 ( click the link to review the publication )

J Physiol, 2019, 597(6):1627-1642

PubMed: 30488437 ( click the link to review the publication )

Mol Biol Cell, 2019, 30(9):1108-1117

PubMed: 30785867 ( click the link to review the publication )

Sci Rep, 2019, 9(1):1897

PubMed: 30760778 ( click the link to review the publication )
Sci Rep, 2019, 9(1):4819

PubMed: 30894630 ( click the link to review the publication )

Sci Rep, 2019, 9(1):17104

PubMed: 31745115 ( click the link to review the publication )

Sci Rep, 2019, 9(1):7617

PubMed: 31110200 ( click the link to review the publication )

Sci Rep, 2019, 9(1):17171

PubMed: 31748572 ( click the link to review the publication )

Nanomaterials (Basel), 2019, 9(12)

PubMed: 31888247 ( click the link to review the publication )

J Proteome Res, 2019, 18(1):522-534

PubMed: 30540191 ( click the link to review the publication )

J Pharmacol Exp Ther, 2019, 369(3):531-545

PubMed: 30898866 ( click the link to review the publication )

J Acquir Immune Defic Syndr, 2019, 82(4):407-415

PubMed: 31658184 ( click the link to review the publication )

BMC Cancer, 2019, 19(1):485

PubMed: 31118072 ( click the link to review the publication )

Molecules, 2019, 24(3)

PubMed: 30754629 ( click the link to review the publication )

Int J Parasitol Drugs Drug Resist, 2019, 9:80-86

PubMed: 30771616 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2019, 84(6):1241-1256

PubMed: 31541266 ( click the link to review the publication )

PLoS One, 2019, 14(2):e0212210

PubMed: 30779812 ( click the link to review the publication )

PLoS One, 2019, 14(2):e0212860

PubMed: 30794695 ( click the link to review the publication )

Leuk Lymphoma, 2019, 60(1):189-199

PubMed: 29741440 ( click the link to review the publication )

Environ Mol Mutagen, 2019, 60(6):513-533

PubMed: 30702769 ( click the link to review the publication )

Exp Hematol, 2019, 77:36-40.e2

PubMed: 31493432 ( click the link to review the publication )

Leuk Res, 2019, 78:12-20

PubMed: 30660961 ( click the link to review the publication )

J Immunol Methods, 2019, 464:22-30

PubMed: 30347189 ( click the link to review the publication )

Oncol Lett, 2019, 18(5):4449-4456

PubMed: 31611954 ( click the link to review the publication )

Cancer Immunol Res, 2019,

PubMed: 31405946 ( click the link to review the publication )

Oncotarget, 2019, 10(31):2930-2946

PubMed: 31105876 ( click the link to review the publication )

Oncotarget, 2019, 10(23):2237-2251

PubMed: 31040916 ( click the link to review the publication )

J Extracell Vesicles, 2019, 9(1):1698889

PubMed: 31853340 ( click the link to review the publication )
Cancer Immunol Res, 2019, 7(9):1523-1534

PubMed: 31266784 ( click the link to review the publication )

Nat Neurosci, 2019, 22(5):719-728

PubMed: 30936558 ( click the link to review the publication )

Cell Mol Gastroenterol Hepatol, 2019, 8(1):37-60

PubMed: 30836148 ( click the link to review the publication )

Nat Biomed Eng, 2018, 2(8):578-588

PubMed: 31015631 ( click the link to review the publication )

Sci Transl Med, 2018, 10(427)

PubMed: 29437150 ( click the link to review the publication )

Nat Chem Biol, 2018, 14(8):768-777

PubMed: 29942081 ( click the link to review the publication )

Nat Commun, 2018, 9(1):1523

PubMed: 29670076 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2018, 115(26):E6030-E6038

PubMed: 29875142 ( click the link to review the publication )

Am J Hum Genet, 2018, 103(6):976-983

PubMed: 30449416 ( click the link to review the publication )

Cell Rep, 2018, 24(13):3607-3618

PubMed: 30257219 ( click the link to review the publication )

Cell Rep, 2018, 25(13):3674-3692.e10

PubMed: 30590041 ( click the link to review the publication )

Elife, 2018, 7e33304

PubMed: 30231971 ( click the link to review the publication )

J Hematol Oncol, 2018, 11(1):85

PubMed: 29925404 ( click the link to review the publication )

Oncogene, 2018, 37(16):2104-2121

PubMed: 29379163 ( click the link to review the publication )

Oncogene, 2018, 37(38):5221-5232

PubMed: 29849118 ( click the link to review the publication )

Oncogene, 2018, 37(21):2837-2849

PubMed: 29511345 ( click the link to review the publication )

Cell Mol Life Sci, 2018, 75(22):4223-4234

PubMed: 29955905 ( click the link to review the publication )

Sci Signal, 2018, 11(557)

PubMed: 30459283 ( click the link to review the publication )

Sci Signal, 2018, 11(539)

PubMed: 30018082 ( click the link to review the publication )

J Exp Clin Cancer Res, 2018, 37(1):183

PubMed: 30081903 ( click the link to review the publication )

EBioMedicine, 2018, 29:112-127

PubMed: 29433983 ( click the link to review the publication )

Cancers (Basel), 2018, 10(12)

PubMed: 30572654 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2018, 31(2):253-266

PubMed: 28972303 ( click the link to review the publication )

Front Immunol, 2018, 9:8

PubMed: 29403492 ( click the link to review the publication )
Front Immunol, 2018, 9:2033

PubMed: 30283437 ( click the link to review the publication )

Endocr Relat Cancer, 2018, 25(4):471-480

PubMed: 29440231 ( click the link to review the publication )

Cell Commun Signal, 2018, 16(1):21

PubMed: 29776413 ( click the link to review the publication )

Oral Oncol, 2018, 78:56-63

PubMed: 29496059 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(10):1556-1567

PubMed: 29903769 ( click the link to review the publication )

J Cell Sci, 2018, 131(22)jcs221788

PubMed: 30404826 ( click the link to review the publication )

Int J Mol Sci, 2018, 19(7)

PubMed: 30036966 ( click the link to review the publication )

Sci Rep, 2018, 8(1):584

PubMed: 29330550 ( click the link to review the publication )

Sci Rep, 2018, 8(1):5362

PubMed: 29599515 ( click the link to review the publication )

Food Chem Toxicol, 2018, 119:464-478

PubMed: 29097117 ( click the link to review the publication )

J Proteome Res, 2018, 17(1):63-75

PubMed: 29164889 ( click the link to review the publication )

Front Pharmacol, 2018, 9:403

PubMed: 29765318 ( click the link to review the publication )

Front Pharmacol, 2018, 9:1081

PubMed: 30319416 ( click the link to review the publication )

Front Pharmacol, 2018, 9:1285

PubMed: 30473665 ( click the link to review the publication )

Int J Oncol, 2018, 52(6):2061-2068

PubMed: 29620253 ( click the link to review the publication )

Cytokine, 2018, 111:209-215

PubMed: 30176559 ( click the link to review the publication )

Cell Adh Migr, 2018, 12(3):286-298

PubMed: 28678601 ( click the link to review the publication )

Toxicol Lett, 2018, 296:39-47

PubMed: 30086328 ( click the link to review the publication )

Transl Oncol, 2018, 11(6):1406-1418

PubMed: 30219696 ( click the link to review the publication )

Cell Biol Int, 2018,

PubMed: 29885023 ( click the link to review the publication )

Oncol Lett, 2018, 15(5):6831-6838

PubMed: 29731862 ( click the link to review the publication )

FEBS Open Bio, 2018, 8(5):732-742

PubMed: 29744288 ( click the link to review the publication )

J Pharmacokinet Pharmacodyn, 2018, 45(3):401-418

PubMed: 29446053 ( click the link to review the publication )

Oncotarget, 2018, 9(5):5545-5561

PubMed: 29464017 ( click the link to review the publication )
Oncotarget, 2018, 9(51):29680-29697

PubMed: 30038713 ( click the link to review the publication )

Oncotarget, 2018, 9(12):10723-10733

PubMed: 29535838 ( click the link to review the publication )

Oncoscience, 2018, 5(1-2):21-38

PubMed: 29556515 ( click the link to review the publication )

Nature, 2018, 563(7730):265-269

PubMed: 30401838 ( click the link to review the publication )

Sci Transl Med, 2017, 9(374)

PubMed: 28123069 ( click the link to review the publication )

Sci Transl Med, 2017, 9(414)10

PubMed: 29093181 ( click the link to review the publication )

Blood, 2017, 129(11):e26-e37

PubMed: 28122742 ( click the link to review the publication )

Mol Cell, 2017, 66(5):635-647

PubMed: 28575659 ( click the link to review the publication )

Nat Commun, 2017, 1;8(1):1232

PubMed: 29089541 ( click the link to review the publication )

Nat Commun, 2017, 8:14073

PubMed: 28102225 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(23):7360-7374

PubMed: 28939749 ( click the link to review the publication )

Leukemia, 2017, 31(5):1253-1254

PubMed: 28465516 ( click the link to review the publication )

Cancer Res, 2017,

PubMed: 27821486 ( click the link to review the publication )

Elife, 2017, 6

PubMed: 28199182 ( click the link to review the publication )

Elife, 2017, 10.7554/eLife.25946

PubMed: 28598329 ( click the link to review the publication )

Int J Cancer, 2017, 140(5):1173-1185

PubMed: 27798955 ( click the link to review the publication )

J Hematol Oncol, 2017, 10(1):118

PubMed: 28606127 ( click the link to review the publication )

Arch Toxicol, 2017, 91(8):2921-2938

PubMed: 28032146 ( click the link to review the publication )

Mol Cancer Ther, 2017,

PubMed: 28830985 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(11):2387-2398

PubMed: 28775147 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(9):1729-1738

PubMed: 28619758 ( click the link to review the publication )

Neoplasia, 2017, 19(4):354-363

PubMed: 28319809 ( click the link to review the publication )

Toxicol Sci, 2017, 162(1):146-166

PubMed: 29106658 ( click the link to review the publication )

Sci Rep, 2017,

PubMed: 28638122 ( click the link to review the publication )
J Biol Chem, 2017, 292(35):14381-14390

PubMed: 28684419 ( click the link to review the publication )

Front Mol Neurosci, 2017, 10:418

PubMed: 29326548 ( click the link to review the publication )

Cancer Med, 2017, 6(4):809-818

PubMed: 28316141 ( click the link to review the publication )

J Appl Toxicol, 2017, 37(3):382-390

PubMed: 27480533 ( click the link to review the publication )

Clin Res Hepatol Gastroenterol, 2017, 41(6):677-686

PubMed: 28578938 ( click the link to review the publication )

PLoS ONE, 2017,

PubMed: 28945796 ( click the link to review the publication )

Onco Targets Ther, 2017, 10:73-83

PubMed: 28123301 ( click the link to review the publication )

J Neurophysiol, 2017, 118(1):595-609

PubMed: 28446585 ( click the link to review the publication )

Eur J Haematol, 2017, 99(5):442-448

PubMed: 28881484 ( click the link to review the publication )

Arch Pharm Res, 2017, 40(2):197-203

PubMed: 27988882 ( click the link to review the publication )

Mol Vis, 2017, 23:823-831

PubMed: 29225458 ( click the link to review the publication )

SLAS Discov, 2017, 22(7):915-922

PubMed: 28346107 ( click the link to review the publication )

Ther Drug Monit, 2017, 39(3):252-262

PubMed: 28490048 ( click the link to review the publication )

Exp Ther Med, 2017,

PubMed: 28810597 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 28977994 ( click the link to review the publication )

Cell Death Dis, 2017, 8(8):e3029

PubMed: 29048432 ( click the link to review the publication )

Cell Stem Cell, 2017, 20(2):233-246

PubMed: 27989769 ( click the link to review the publication )

Oncotarget, 2017, 8(52):90262-90277

PubMed: 29163826 ( click the link to review the publication )

Oncotarget, 2017, 8(27):43662-43677

PubMed: 28599273 ( click the link to review the publication )

Leuk Lymphoma, 2017, 58(8):1903-1913

PubMed: 27931141 ( click the link to review the publication )

Hepatology, 2017, 66(6):1934-1951

PubMed: 28714104 ( click the link to review the publication )

Oncotarget, 2017, 8(47):81794-81802

PubMed: 29137222 ( click the link to review the publication )

Blood Adv, 2017, 1(26):2610-2623

PubMed: 29296914 ( click the link to review the publication )

Cell Host Microbe, 2017, 21(6):754-768

PubMed: 28618271 ( click the link to review the publication )
Oncotarget, 2017, 8(43):73871-73883

PubMed: 29088753 ( click the link to review the publication )

Nat Commun, 2016, 7:10060

PubMed: 26725982 ( click the link to review the publication )

Nat Commun, 2016, 7:11889

PubMed: 27297662 ( click the link to review the publication )

Nat Commun, 2016, 7:12428

PubMed: 27687249 ( click the link to review the publication )

EMBO Mol Med, 2016, 1;8(2):105-16

PubMed: 26758680 ( click the link to review the publication )

Leukemia, 2016, 30(6):1273-81

PubMed: 26987906 ( click the link to review the publication )

Leukemia, 2016, 30(7):1493-501

PubMed: 27044711 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2016, 113(51):E8228-E8237

PubMed: 27930322 ( click the link to review the publication )

Cancer Res, 2016, 76(12):3520-30

PubMed: 27197167 ( click the link to review the publication )

Cancer Res, 2016, 76(4):974-83

PubMed: 26837769 ( click the link to review the publication )

Int J Cancer, 2016, 139(10):2359-69

PubMed: 27434411 ( click the link to review the publication )

Cancer Lett, 2016, 376(1):188-96

PubMed: 26996299 ( click the link to review the publication )

Sci Signal, 2016, 9(456):ra116

PubMed: 27899526 ( click the link to review the publication )

Breast Cancer Res, 2016, 18(1):80

PubMed: 27495374 ( click the link to review the publication )

Oncoimmunology, 2016, 5(12):e1240858

PubMed: 28123877 ( click the link to review the publication )

Development, 2016, 143(10):1674-87

PubMed: 26989177 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(7):1472-84

PubMed: 27364904 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(5):819-29

PubMed: 26883271 ( click the link to review the publication )

J Infect Dis, 2016, 213(11):1767-76

PubMed: 26802142 ( click the link to review the publication )

Hum Mol Genet, 2016, 25(2):266-74

PubMed: 26604135 ( click the link to review the publication )

Psychoneuroendocrinology, 2016, 66:138-49

PubMed: 26803529 ( click the link to review the publication )

Biochim Biophys Acta, 2016, 1862(11):2158-2167

PubMed: 27565738 ( click the link to review the publication )

Sci Rep, 2016, 6:26252

PubMed: 27188220 ( click the link to review the publication )

Stem Cells Int, 2016, 2016:9601493

PubMed: 26788073 ( click the link to review the publication )
BMC Cancer, 2016, 16:229

PubMed: 26984511 ( click the link to review the publication )

PLoS One, 2016, 11(10):e0164895

PubMed: 27768734 ( click the link to review the publication )

Oncol Lett, 2016, 12(5):3598-3608

PubMed: 27900042 ( click the link to review the publication )

Assay Drug Dev Technol, 2016, 14(7):395-406

PubMed: 27552144 ( click the link to review the publication )

Oncotarget, 2016, 7(29):45916-45925

PubMed: 27322141 ( click the link to review the publication )

Oncotarget, 2016,

PubMed: 27602951 ( click the link to review the publication )

Oncotarget, 2016, 7(47):78083-78094

PubMed: 27801667 ( click the link to review the publication )

Oncotarget, 2016,

PubMed: 27756880 ( click the link to review the publication )

Oncotarget, 2016,

PubMed: 27687593 ( click the link to review the publication )

J Gen Virol, 2016, 97(5):1134-1144

PubMed: 26879209 ( click the link to review the publication )

Oncotarget, 2016, 7(37):59236-59244

PubMed: 27494860 ( click the link to review the publication )

Oncotarget, 2016, 7(17):24483-94

PubMed: 27016416 ( click the link to review the publication )

Oncotarget, 2016, 7(18-:25983-6002

PubMed: 27036020 ( click the link to review the publication )

Oncotarget, 2016, 7(20):29199-210

PubMed: 27078848 ( click the link to review the publication )

Oncotarget, 2016,

PubMed: 26623721 ( click the link to review the publication )

Sci Transl Med, 2015, 7(284):284ra57

PubMed: 25904741 ( click the link to review the publication )

Blood, 2015, 125(8):1282-91

PubMed: 25515960 ( click the link to review the publication )

Leukemia, 2015, 29(3):586-597

PubMed: 25134459 ( click the link to review the publication )

Cancer Lett, 2015, 10.1016/j.canlet.2015.02.044

PubMed: 25737303 ( click the link to review the publication )

Arterioscler Thromb Vasc Biol, 2015, 35(11):2326-35

PubMed: 26359510 ( click the link to review the publication )

Cell Death Dis, 2015, 6:e1767

PubMed: 25996294 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(10):2292-302

PubMed: 26294741 ( click the link to review the publication )

Radiother Oncol, 2015, 116(3):431-7

PubMed: 26320552 ( click the link to review the publication )

Hum Mol Genet, 2015, 24(15):4296-305

PubMed: 25948553 ( click the link to review the publication )
ACS Chem Biol, 2015, 10(1):262-8

PubMed: 25248068 ( click the link to review the publication )

ACS Chem Biol, 2015, 10(1):262-8

PubMed: ( click the link to review the publication )

Eur Neuropsychopharmacol, 2015, 25(8):1275-86

PubMed: 25983018 ( click the link to review the publication )

J Cell Sci, 2015, 128(2):251-65

PubMed: ( click the link to review the publication )

Eur Neuropsychopharm, 2015, 10.1016/j.euroneuro.2015.04.021

PubMed: ( click the link to review the publication )

Biochem J, 2015, 465(2):271-9

PubMed: 25351958 ( click the link to review the publication )

Clin Immunol, 2015, 157(2):205-215

PubMed: 25728491 ( click the link to review the publication )

Invest Ophthalmol Vis Sci, 2015, 56(9):5457-64

PubMed: 26284551 ( click the link to review the publication )

Neurotox Res, 2015, 27(4):384-98

PubMed: 25782580 ( click the link to review the publication )

Arch Biochem Biophys, 2015, 10.1016/j.taap.2015.03.018

PubMed: 25843419 ( click the link to review the publication )

PLoS One, 2015, 10(6):e0129663

PubMed: 26061184 ( click the link to review the publication )

Exp Hematol, 2015,

PubMed: 25641047 ( click the link to review the publication )

Pulm Pharmacol Ther, 2015, 10.1016/j.pupt.2015.03.001

PubMed: 25843005 ( click the link to review the publication )

Leuk Res, 2015, 10.1016/j.leukres.2015.08.007

PubMed: 26346348 ( click the link to review the publication )

Mol Med Rep, 2015, 12(3):3249-3256

PubMed: 25975261 ( click the link to review the publication )

Int J Clin Exp Pathol, 2015, 8(7):7818-24

PubMed: 26339346 ( click the link to review the publication )

Childs Nerv Syst, 2015, 31(2):221-6

PubMed: 25269544 ( click the link to review the publication )

Childs Nerv Syst, 2015, 31(4):557-62

PubMed: 25712742 ( click the link to review the publication )

Childs Nerv Syst, 2015, 31(2):221-6

PubMed: ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 26325669 ( click the link to review the publication )

Oncotarget, 2015, 6(4):1967-80

PubMed: 25596742 ( click the link to review the publication )

Eur J Pharm Sci, 2015, 80:56-65

PubMed: 26296860 ( click the link to review the publication )

Oncotarget, 2015, 6(7):5118-33

PubMed: 25742786 ( click the link to review the publication )

Oncotarget, 2015, 6(36):38854-65

PubMed: 26513174 ( click the link to review the publication )
J Virol, 2015, 90(4):1918-30

PubMed: 26656684 ( click the link to review the publication )

Oncotarget, 2015, 6(14):12405-20

PubMed: 25915159 ( click the link to review the publication )

Blood, 2014, 123(21):3296-304

PubMed: 24723681 ( click the link to review the publication )

Nat Commun, 2014, 5:3384

PubMed: 24594970 ( click the link to review the publication )

Leukemia, 2014, 28(10):2109-12

PubMed: 24919804 ( click the link to review the publication )

Cell Rep, 2014, 8(4):1037-48

PubMed: 25127139 ( click the link to review the publication )

Elife, 2014, 3:e02523

PubMed: 24844246 ( click the link to review the publication )

Oncogene, 2014,

PubMed: 23318431 ( click the link to review the publication )

Br J Pharmacol, 2014, 171(24):5757-73

PubMed: 25117211 ( click the link to review the publication )

Cancer Lett, 2014, 344(1):90-100

PubMed: 24513268 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1005

PubMed: 24434513 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1023

PubMed: 24457967 ( click the link to review the publication )

Cell Death Dis, 2014, 6:e1595

PubMed: 25590805 ( click the link to review the publication )

Stem Cells, 2014, 32(9):2324-37

PubMed: 24806995 ( click the link to review the publication )

J Cell Sci, 2014, 127(Pt 14):3039-51

PubMed: 24928894 ( click the link to review the publication )

Int J Mol Sci, 2014, 15(4):5838-51

PubMed: 24714091 ( click the link to review the publication )

Exp Cell Res, 2014, 328(1):20-31

PubMed: 25128812 ( click the link to review the publication )

Cell Cycle, 2014,

PubMed: 24196445 ( click the link to review the publication )

J Pharm Biomed Anal, 2014, 94:125-31

PubMed: 24561338 ( click the link to review the publication )

PLoS One, 2014, 9(10):e111146

PubMed: 25343454 ( click the link to review the publication )

PLoS One, 2014, 9(9):e107367

PubMed: 25198091 ( click the link to review the publication )

PLoS One, 2014, 9(1):e85485

PubMed: 24427313 ( click the link to review the publication )

Mol Biosyst, 2014, 10.1039/C4MB00224E

PubMed: 25099472 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 455(3-4):256-61

PubMed: 25449280 ( click the link to review the publication )
Leuk Lymphoma, 2014, 10.3109/10428194.2014.898759

PubMed: 24597981 ( click the link to review the publication )

Pharmacogenet Genomics, 2014, 24(1):52-61

PubMed: 24322003 ( click the link to review the publication )

Biochem Biophy Res Co, 2014, 10.1016/j.bbrc.2014.11.002

PubMed: ( click the link to review the publication )

Head Neck, 2014, 36(3):375-84

PubMed: 23729178 ( click the link to review the publication )

Graefes Arch Clin Exp Ophthalmol, 2014, 10.1007/s00417-014-2674-7

PubMed: 24874745 ( click the link to review the publication )

Mol Med Rep, 2014, 10(5):2729-35

PubMed: 25199623 ( click the link to review the publication )

Head Neck, 2014, 10.1002/hed.23822.

PubMed: 24986420 ( click the link to review the publication )

Oncoscience, 2014, 1(1):57-68

PubMed: 25593988 ( click the link to review the publication )

Oncotarget, 2014, 5(15):5908-19

PubMed: 25115383 ( click the link to review the publication )

J Exp Med, 2013, 210(11):2205-21

PubMed: 24127489 ( click the link to review the publication )

J Exp Med, 2013, 210(12):2569-82

PubMed: 24190431 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(18):5053-67

PubMed: 23900136 ( click the link to review the publication )

PLoS Biol, 2013, 11(3):e1001515

PubMed: 23526884 ( click the link to review the publication )

Cancer Lett, 2013, 340(1):43-50

PubMed: 23811285 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2013, 26(4):518-26

PubMed: 23582185 ( click the link to review the publication )

Neoplasia, 2013, 15(11):1272-81

PubMed: 24339739 ( click the link to review the publication )

J Thorac Cardiovasc Surg, 2013, 145(2):531-8

PubMed: 23142123 ( click the link to review the publication )

J Neurochem, 2013, 12(12):2864-73

PubMed: 24130049 ( click the link to review the publication )

J Biol Chem, 2013, 288(8):5553-61

PubMed: 23303179 ( click the link to review the publication )

Int J Oncol, 2013, 43(6):2064-72

PubMed: 24126464 ( click the link to review the publication )

Proteomics, 2013, 13(23-24):3554-62

PubMed: 24167056 ( click the link to review the publication )

Cell Adh Migr, 2013, 7(4):362-9

PubMed: 23751956 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2013, 72(1):35-44

PubMed: 23712327 ( click the link to review the publication )

Mol Biosyst, 2013, 9(2):234-45

PubMed: 23168618 ( click the link to review the publication )
Pharmgenomics Pers Med, 2013, 6:63-72

PubMed: 24019750 ( click the link to review the publication )

Sci Rep, 2013, 3:2100

PubMed: 23812503 ( click the link to review the publication )

Cell Cycle, 2013, 12(18):2978-91

PubMed: 23974111 ( click the link to review the publication )

Sci Transl Med, 2012, 4(136):136ra70

PubMed: 22649091 ( click the link to review the publication )

Blood, 2012, 119(21):4981-91

PubMed: 22411867 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(1):127-39

PubMed: 22090359 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2012, 109(17):6584-10

PubMed: 22492965 ( click the link to review the publication )

Oncogene, 2012, 32(37):4331-42

PubMed: 23085751 ( click the link to review the publication )

Br J Haematol, 2012, 157(4):510-4

PubMed: 22313359 ( click the link to review the publication )

J Virol, 2012, 86(16):8765-72

PubMed: 22696643 ( click the link to review the publication )

Angiogenesis, 2012, 15(1):33-45

PubMed: 22203239 ( click the link to review the publication )

Cancer Immunol Immun, 2012, 61(2):193-202

PubMed: 21874302 ( click the link to review the publication )

Invest New Drugs, 2012, 30(1):417-22

PubMed: 20953816 ( click the link to review the publication )

Stem Cells Dev, 2012, 21(16):2939-48

PubMed: 22642671 ( click the link to review the publication )

Hematol Oncol, 2012, 31(3):156-63

PubMed: 23108877 ( click the link to review the publication )

PLoS One, 2012, 7(7):e40853

PubMed: 22815843 ( click the link to review the publication )

J Biomol Screen, 2012, 18(4):388-99

PubMed: 23134735 ( click the link to review the publication )

J Liq Chromatogr R T, 2012, 2503-2510

PubMed: ( click the link to review the publication )

Oncotarget, 2012, 3(12):1557-65

PubMed: 23238683 ( click the link to review the publication )

Cell Res, 2011, 21(7):1080-7

PubMed: 21423276 ( click the link to review the publication )

J Mol Biol, 2011, 411(2):474-85

PubMed: 21699901 ( click the link to review the publication )

J Virol, 2011, 85(5):2296-303

PubMed: 21177802 ( click the link to review the publication )

Cancer Prev Res , 2011, 4(8):1222-32

PubMed: 21546539 ( click the link to review the publication )

J Biol Chem, 2011, 286(16):13846-51

PubMed: 21343293 ( click the link to review the publication )
Exp Hematol, 2011, 39(8):859-65.e2

PubMed: 21689725 ( click the link to review the publication )

PLoS One, 2010, 5(11):e14143

PubMed: 21152443 ( click the link to review the publication )

产品安全说明书

Src抑制剂选择性比较

生物活性

产品描述

靶点

Abl ^[1] (Cell-free assay)	Src ^[1] (Cell-free assay)	c-Kit (D816V) ^[2] (Cell-free assay)	c-Kit (wt) ^[2] (Cell-free assay)
0.6 nM	0.8 nM	37 nM	79 nM

体外研究

在抑制表达野生型Bcr-Abl或全部Bcr-Abl突变型（除了T315I）的Ba/F3增殖时，Dasatinib效果比Imatinib高很多。与Imatinib相比，Dasatinib呈2倍指数增长效力(约325倍)。Dasatinib有效抑制野生型Abl 激酶和全部突变型（除了T315I）。Dasatinib 直接靶向作用于野生型和突变型Abl激酶域，且抑制自磷酸化和底物磷酸化，这种作用存在浓度依赖性。Dasatinib作用于表达野生型 Bcr-Abl的细胞时，效果比Imatinib高325倍多。^[1] TgE骨髓细胞菌落百分数从未处理孔的100% 降低到Dasatinib处理孔的4.12%。有 Dasatinib存在时, WT 和TgE骨髓细胞形成的菌落百分数明显不同。LMP2A的表达可促进 B 淋巴细胞存活和增殖，而Dasatinib通过靶向作用于Lyn 和/或c-Abl 激酶可抑制以上存活和增殖。^[2] Dasatinib 处理一系列甲状腺癌细胞，抑制Src信号, 降低生长速度,使细胞周期停滞，且诱导凋亡。使用剂量不断增加的 Dasatinib (0.019 μM 到 1.25 μM) 处理C643, TPC1, BCPAP, 和 SW1736 细胞3天，抑制50%细胞生长，然而抑制K1细胞系生长则需更高浓度Dasatinib。使用10 nM 或50 nM Dasatinib 处理BCPAP，SW1736 和 K1 细胞，导致G1期细胞提高9-22%，而S期细胞百分数则降低7-18%。^[3]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
M07ep210	M4Xldmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NIntcpE4OiCq	NUnSPHQ2TE2VTx?=	NYf3SVN2UUN3ME2wMlAxODB5IN88US=>	Ml2yQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd7NU[wPFAoRjF5OUW2NFgxRC:jPh?=
K562	NGDQWZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M2PobVczKGh?	MV;EUXNQ	M1HqUWlEPTB;MD6wNFEh\|ryP	NFHlNZE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{m1OlA5OCd-MUe5OVYxQDB:L3G+
M07e	NHHsNWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NF;TV3M4OiCq	MoXDSG1UVw>?	MWjJR\|UxRTBwMECxNkDPxE1?	M120NFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5OUW2NFgxLz5zN{m1OlA5ODxxYU6=
ALL3	MlHzR5l1d3SxeHnjJGF{e2G7	NFi1e5UxNjIQvF2=	NVTF[Y8{PzJiaB?=	MXjEUXNQ	MVfJR\|UxRTBwMECwOEDPxE1?	NVe2NItvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm4PFk2PDBpPkG5PFg6PTRyPD;hQi=>
CML	NUjyd3hMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MnTZNlAhdWmw	M2CyU2ROW09?	NGHWeGVKSzVyPUCuNFAyKM7:TR?=	Mn7EQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl{MUmwNVYoRjF7MkG5NFE3RC:jPh?=
BA/F3	MmK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NFzzUVU4OiCq	MW\EUXNQ	MYHJR\|UxRTZwNUi5JO69VQ>?	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzB6OE[0OEc,OjNyOEi2OFQ9N2F-
BA/F3	Mli2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NF3xVmk4OiCq	M2H6XmROW09?	M{SxdWlv\HWlZYOgZY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDtc5V{\SCEQT;GN{Bk\WyuczDlfJBz\XO\|aX7nJGJkei2DYnygUVM2OVRibYX0ZY51KHerdHigTWM2OCCxZjCwMlAxODh\|zszN	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzB6OE[0OEc,OjNyOEi2OFQ9N2F-
BA/F3	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NXnrd2x7PzJiaB?=	NWq1b\|ZwTE2VTx?=	M3zEfGlv\HWlZYOgZY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDtc5V{\SCEQT;GN{Bk\WyuczDlfJBz\XO\|aX7nJJdqdGRidInw[UBD[3JvQXLsJJdqfGhiSVO1NEBw\iByLkCwOFXPxE1?	NYfEVHFlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOwPFg3PDRpPkKzNFg5PjR2PD;hQi=>
BA/F3	MmjpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M{Xr[lczKGh?	M13aVWROW09?	NIrheVZKdmS3Y3XzJIFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgcY92e2ViQlGvSlMh[2WubIOg[ZhxemW\|c3nu[{BD[3JvQXLsJHQ{OTWLIH31eIFvfCC5aYToJGlEPTBib3[gNU44OTUQvF2=	NGrJ[4U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{C4PFY1PCd-MkOwPFg3PDR:L3G+
BA/F3	NF;4Z4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		Mn24O\|IhcA>?	Mn7XSG1UVw>?	MoLmTY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W\|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKEKFUj3BRmwhTjR6NmOgcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iByLkCwNFnPxE1?	MoLNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN\|MEG3NFMoRjJ\|M{CxO\|A{RC:jPh?=
BA/F3	MmfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MWS3NkBp	MXnEUXNQ	M3yxTWlv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yCEQ2KtRWJNKEV{NUXLJI12fGGwdDDhd5Nme3OnZDDhd{Boem:5dHigTY5pcWKrdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFMz\|ryP	NHzUPFI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{OwNVcxOyd-MkOzNFE4ODN:L3G+
BA/F3	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NV7DPWNKPzJiaB?=	MULEUXNQ	NEnHcFZKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z\|IHPlcIx{KGW6cILld5NqdmdiQlPSMWFDVCCJMkWwSUBufXSjboSgZZN{\XO\|ZXSgZZMh\3Kxd4ToJGlvcGmkaYTpc44hf2m2aDDJR\|UxKG:oIECuNFA2Oc7:TR?=	NXTCUpJtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzNFE4ODNpPkKzN\|AyPzB\|PD;hQi=>
BA/F3	NHO4dGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MkHHO\|IhcA>?	NIfNSXBFVVOR	NVK0PIcxUW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIFLDVk1CSkxiUUK1NmghdXW2YX70JIF{e2W\|c3XkJIF{KGe{b4f0bEBKdmirYnn0bY9vKHerdHigTWM2OCCxZjCwMlAxQM7:TR?=	NULLem82RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzNFE4ODNpPkKzN\|AyPzB\|PD;hQi=>
BA/F3	M{PPXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NXjxU3oyPzJiaB?=	MljSSG1UVw>?	MnLwTY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W\|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKEKFUj3BRmwhTTN3OW[gcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iByLkCwNVPPxE1?	NUGzTHFTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzNFE4ODNpPkKzN\|AyPzB\|PD;hQi=>
BA/F3	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NFXTZlE4OiCq	M3HaV2ROW09?	Ml;TTY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W\|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKHerbHSgeJlx\SCEQ2KtRWJNKGG\|c3Xzd4VlKGG\|IHfyc5d1cCCLbnjpZol1cW:wIIfpeIghUUN3MDDv[kAxNjByMUpOwG0>	NYrHbXR[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzNFE4ODNpPkKzN\|AyPzB\|PD;hQi=>
BA/F3	NVHqUoJuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NXrzcmI{PzJiaB?=	MVrEUXNQ	NXfRe\|VRUW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIFLDVk1CSkxiWUK1N2ghdXW2YX70JIF{e2W\|c3XkJIF{KGe{b4f0bEBKdmirYnn0bY9vKHerdHigTWM2OCCxZjCwMlAxOjQQvF2=	NFPNR3k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{OwNVcxOyd-MkOzNFE4ODN:L3G+
BA/F3	M3zjT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M17LRlczKGh?	NIjXSodFVVOR	MkfnTY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W\|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKEKFUj3BRmwhXDNzNVmgcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iB\|LkdOwG0>	M2DLZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{CxO\|A{Lz5{M{OwNVcxOzxxYU6=
BA/F3	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M{TZVFczKGh?	M{Lpd2ROW09?	NFTkfW5KdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z\|IHPlcIx{KGG\|c3Xzd4VlKGG\|IHfyc5d1cCCLbnjpZol1cW:wIIfpeIghUUN3MDDv[kAzNjYQvF2=	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzNyMUewN{c,OjN\|MEG3NFM9N2F-
T cell	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MXy3NkBp	M{S5fWROW09?	NWLCUmlpUW6qaXLpeJMh[W62aTDDSFMuKGGwZDDhcpRqKEOGMkitbY5lfWOnZDDUJINmdGxicILvcIln\XKjdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFPPxE1?	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzF3NEWxNkc,OTdzNUS1NVI9N2F-
WiDr	MlLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MlnDO\|IhcA>?	NHHLZY5FVVOR	M1HNcmlEPTB;MD6wOVIh\|ryP	M1HXTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF3NkG1OVEzLz5zNU[xOVUyOjxxYU6=
PC3	NF;nSnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M4izZ\|czKGh?	NV;xeo5xTE2VTx?=	NX;WUIt7UUN3ME2wMlAxQTRizszN	MmjxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTV4MUW1NVIoRjF3NkG1OVEzRC:jPh?=
MDA-MB-231	NGDUfVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NHvZZnY4OiCq	NXjqeoI3TE2VTx?=	MVrJR\|UxRTBwMEGyJO69VQ>?	M{TmOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF3NkG1OVEzLz5zNU[xOVUyOjxxYU6=
Hs578T	Mn\qR5l1d3SxeHnjJGF{e2G7		MV63NkBp	NVXPXJlyTE2VTx?=	NVHYOmJmT0l3ME2wMlA{KM7:TR?=	NWn0fJVrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwNVU{OjdpPkK0NFE2OzJ5PD;hQi=>
HMEC	MYnDfZRwfG:6aXOgRZN{[Xl?		MVG3NkBp	NX7RXWNYTE2VTx?=	MYHHTVUxRTFwODFOwG0>	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDBzNUOyO{c,OjRyMUWzNlc9N2F-
DU145	MlK1R5l1d3SxeHnjJGF{e2G7		M3LIRVczKGh?	M37wOmROW09?	NV3OcmZ1T0l3ME2wMlE3KM7:TR?=	M{LxdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEG1N\|I4Lz5{NECxOVMzPzxxYU6=
U251	NIXJcYtEgXSxdH;4bYMhSXO\|YYm=		NE\qdoo4OiCq	M1XwWGROW09?	NG\2WYNIUTVyPUKuPFEh\|ryP	Mmm0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyMUWzNlcoRjJ2MEG1N\|I4RC:jPh?=
NCI60	MWTDfZRwfG:6aXOgRZN{[Xl?		M1LXZlczKGh?	NWLoPYNGTE2VTx?=	NHW5dnFIUTVyPUWuO{DPxE1?	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDBzNUOyO{c,OjRyMUWzNlc9N2F-
MALME-3M	M3PEUWN6fG:2b4jpZ{BCe3OjeR?=		Ml2zO\|IhcA>?	M2rkfWROW09?	NIfufmVIUTVyPU[uOlEh\|ryP	MnKyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyMUWzNlcoRjJ2MEG1N\|I4RC:jPh?=
KM12	NFjnVFJEgXSxdH;4bYMhSXO\|YYm=		NY\CbZpMPzJiaB?=	Mki2SG1UVw>?	M1jtPWdKPTB;Nz60OEDPxE1?	NVjJNVRwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwNVU{OjdpPkK0NFE2OzJ5PD;hQi=>
SW620	MV7DfZRwfG:6aXOgRZN{[Xl?		NFPTN3Q4OiCq	M4HzWmROW09?	M2DzeGdKPTB;OD60N{DPxE1?	M165c\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEG1N\|I4Lz5{NECxOVMzPzxxYU6=
RXF 393NL	MVvDfZRwfG:6aXOgRZN{[Xl?		MVq0JIRigXN?	NFHuRYZFVVOR	MV\JR\|UxRTBwMEKxO{DPxE1?	MknQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN{NUOwO\|QoRjJ\|MkWzNFc1RC:jPh?=
LXFA 983L	NVm3eFU{S3m2b4TvfIlkKEG\|c3H5		NFfP[pM1KGSjeYO=	NVryUnp{TE2VTx?=	M3nZPGlEPTB;MD6wOVY2KM7:TR?=	M{LLNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MkWzNFc1Lz5{M{K1N\|A4PDxxYU6=
PRXF DU145	NYj4Zm0yS3m2b4TvfIlkKEG\|c3H5		NHzIRpA1KGSjeYO=	NHXmUY9FVVOR	MkDRTWM2OD1yLkC2NlMh\|ryP	M2WyOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MkWzNFc1Lz5{M{K1N\|A4PDxxYU6=
PAXF 1657L	MomxR5l1d3SxeHnjJGF{e2G7		MkHmOEBl[Xm\|	M3j5W2ROW09?	NGS2fZdKSzVyPUCuNVIyKM7:TR?=	MkG1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN{NUOwO\|QoRjJ\|MkWzNFc1RC:jPh?=
CXF 1103L	NWPQZ3pvS3m2b4TvfIlkKEG\|c3H5		NHHKZVU1KGSjeYO=	Mnr4SG1UVw>?	MWLJR\|UxRTRwM{[g{txO	NX7YTFFwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOyOVMxPzRpPkKzNlU{ODd2PD;hQi=>
GXF251L	MnfOR5l1d3SxeHnjJGF{e2G7		Mmm5OEBl[Xm\|	NH76UYRFVVOR	MYDJR\|UxRTJwMkWg{txO	M4X5c\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MkWzNFc1Lz5{M{K1N\|A4PDxxYU6=
NCI-H23	MnXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MoPQO\|IhcA>?	MXvEUXNQ	MWnJR\|UxRTJwMkeg{txO	NYHCS4JlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1NlExOjBpPkKzOVIyODJyPD;hQi=>
HCT116	NHPlXmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NF\WbJE4OiCq	MVHEUXNQ	MUfJR\|UxRTJwMzFOwG0>	NV7DNXZpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1NlExOjBpPkKzOVIyODJyPD;hQi=>
MCF7	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MYK3NkBp	MnXKSG1UVw>?	M360PWlEPTB;Mj61O{DPxE1?	NHjBSFU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{WyNVAzOCd-MkO1NlExOjB:L3G+
NCI-H460	NXHkR2c3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MmTqO\|IhcA>?	NV[1V3o4TE2VTx?=	MYrJR\|UxRThwOUmg{txO	NUDsXHVqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1NlExOjBpPkKzOVIyODJyPD;hQi=>
DLD1	M{TIRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		Ml;1O\|IhcA>?	NVnuUmtETE2VTx?=	M4Txe2lEPTB;ND62JO69VQ>?	M{OwT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NU[3PVYxLz5{M{W2O\|k3ODxxYU6=
NCI-H661	NHq0ZYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NYn6cnVKPzJiaB?=	M3S0dGROW09?	MlOxTWM2OD15Lkig{txO	NIXpVoM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{W2O\|k3OCd-MkO1Olc6PjB:L3G+
A549	NWjPb2hPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MoSxO\|IhcA>?	MUDEUXNQ	NFjzcVVKSzVyPUiuNkDPxE1?	NX34[o82RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1Olc6PjBpPkKzOVY4QTZyPD;hQi=>
U937	NXLz[XhIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NVGybI1nPzJiaB?=	M3fZTGROW09?	MnvVTWM2OD1zMj6yJO69VQ>?	NIntO2o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{W2O\|k3OCd-MkO1Olc6PjB:L3G+
HEK293	NUK2NXJOTnWwY4Tpc44hSXO\|YYm=	MYCxNOKh\|ryP		MYHEUXNQ	MlPJTY5lfWOnczDibY5lcW6pIHHm[olvcXS7IITvJIh2dWGwIH\1cIwudGWwZ4ToJGhqey22YXfn[YQhVXm2MTDrbY5ie2ViZYjwdoV{e2WmIHnuJGhGUzJ7MzDj[YxteyC5aYToJGlEPTBib3[gNE4xPjQQvF2=	NE\pXY89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mke3NFYyOCd-MkK3O\|A3OTB:L3G+
HUVEC	MkXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX2wMlE2yqEQvF2=	MmfjO\|IhcA>?	M4rDeWROW09?	MX;JcoR2[2W\|IHHueIlidmerb3flcolkKGGldHn2bZR6KGmwIFjVWmVEKGOxLXP1cJR2emWmIIfpeIghfmG\|Y4XsZZIhe22xb4ToJI12e2OuZTDj[YxteyCjc4Pld5Nm\CCjczDJcohq[mm2aX;uJI9nKGOnbHyg[5Jwf3SqIHH0JFAvOTVidV2=	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjh3M{m5N{c,OjJ6NUO5PVM9N2F-
HUVEC	NYf2d2JnTnWwY4Tpc44hSXO\|YYm=	NX\NXmNJOTYEoN88US=>	M36yW\|czKGh?	NGK0dm1FVVOR	MoWwTY5lfWOnczDhcpRq[W6paX;n[Y5q[yCjY4Tpeol1gSCrbjDIWXZGSyClbz3jeYx1fXKnZDD3bZRpKH[jc3P1cIFzKHOvb3;0bEBufXOlbHWgZ4VtdHNiYYPz[ZN{\WRiYYOgTY5pcWKrdHnvckBw\iCwZYT3c5JsKG[xcn3heIlwdiCjdDCxMlghfG9iMUWgeW0>	M1PkZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OEWzPVk{Lz5{Mki1N\|k6OzxxYU6=
Plasmodium falciparum	MVPGeY5kfGmxbjDBd5NigQ>?	MYmxNOKh\|ryP	MV[xOUBucW5?	MWLEUXNQ	MXPJcohq[mm2czDQcIF{dW:maYXtJIZidGOrcHHyeY0heHKxbHnm[ZJifGmxbjDifUBqdmirYnn0bY5oKHSqZTDGeY5kfGmxbjDv[kBR\kOGUFuxJJBzd3SnaX6ge4l1cCCLQ{WwJI9nKDFwMUhOwG0>	NEnre289[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEW1NFM{OCd-MkS1OVA{OzB:L3G+
PC3	NVnsSIpETnWwY4Tpc44hSXO\|YYm=	MoH4NE4yKM7:TR?=	NF22clI2KGh?	NED4cVVFVVOR	M2[3b2lvcGmkaYTzJIh2dWGwIGDDN{Bk\WyuIHHkbIV{cW:wIHH0JFExOCCwTR?=	NE[4cWo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUS2Nlk4PSd-MUm0OlI6PzV:L3G+
DU145	M3q1W2Z2dmO2aX;uJGF{e2G7	MWSwMlEh\|ryP	M{fwWFUhcA>?	MWfEUXNQ	NVS0UmVzUW6qaXLpeJMhcHWvYX6gSHUyPDViY3XscEBi\Ginc3nvckBifCBzMECgcm0>	MoHVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl2NkK5O\|UoRjF7NE[yPVc2RC:jPh?=
PC3	Mme0T4lv[XOnIFHzd4F6	MlLrNE4yKM7:TR?=	NXHmcFFDPSCq	M1fvU2ROW09?	MVrJcohq[mm2czDjV5JkKGmwIHj1cYFvKFCFMzDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gc4YheGixc4Doc5J6dGG2ZXSgV5JkKFl2MU[gcIV3\WxiYYSgNVAxKG6P	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTR4Mkm3OUc,OTl2NkK5O\|U9N2F-
DU145	M4m1bGtqdmG\|ZTDBd5NigQ>?	NYLxVXhOOC5zIN88US=>	MXK1JIg>	M1TlUWROW09?	MVzJcohq[mm2czDjV5JkKGmwIHj1cYFvKESXMUS1JINmdGy\|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBw\iCyaH;zdIhwenmuYYTl[EBUemNiWUSxOkBt\X[nbDDheEAyODBibl2=	NXLWXXV{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm0OlI6PzVpPkG5OFYzQTd3PD;hQi=>
PC3	M3rKT2tqdmG\|ZTDBd5NigQ>?	NU\t[YVSOC5zIN88US=>	MWm1JIg>	M4\FeGROW09?	NYO3R21XUW6qaXLpeJMh[1O{YzDpckBpfW2jbjDQR\|Mh[2WubIOgZZN{\XO\|ZXSgZZMhemWmdXP0bY9vKG:oIIDoc5NxcG:{eXzheIVlKE[DSzDZOVc3N1l3N{egcIV3\WxiYYSgNVAxKG6P	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTR4Mkm3OUc,OTl2NkK5O\|U9N2F-
DU145	NVeycY9KU2mwYYPlJGF{e2G7	MkjlNE4yKM7:TR?=	M2XYcVUhcA>?	M2[3VmROW09?	M4nVWmlvcGmkaYTzJINUemNiaX6gbJVu[W5iRGWxOFUh[2WubIOgZZN{\XO\|ZXSgZZMhemWmdXP0bY9vKG:oIIDoc5NxcG:{eXzheIVlKE[DSzDZOVc3N1l3N{egcIV3\WxiYYSgNVAxKG6P	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTR4Mkm3OUc,OTl2NkK5O\|U9N2F-
Huh7	MnT5RY51cX[rcnHsJGF{e2G7	MWSyMlUh\|ryP	NIjpe\|g1KGSjeYO=	NHfXTJZFVVOR	NHvvZZNKdmirYnn0d{B3cXKjbDDzdJJm[WRiaX6gSIVv\3WnII\pdpV{NWmwZnXjeIVlKGi3bXHuJGh2cDdiY3XscJMh[XO\|ZYPz[YQh[XNiYXPjeY12dGG2aX;uJI9nKH[rcnHsJIVvfmWub4DlJJBzd3SnaX6ge4l1cGmwIIDldolvfWOuZXHyJJJm\2mxbjDheEAzNjVidV2=	NV:4VXNCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUezOlA3PzZpPkG3N\|YxPjd4PD;hQi=>
C6/36	NXrqZXg2SW62aY\pdoFtKEG\|c3H5	NHnDOIozNjVizszN	MWC0JIRigXN?	NUHQdoxGTE2VTx?=	NIDQN4FKdmirYnn0d{B3cXKjbDDzdJJm[WRiaX6gSIVv\3WnII\pdpV{NWmwZnXjeIVlKGG\|aXHuJJRq\2W{IH3vd5F2cXSxIFO2M\|M3KGOnbHzzJIF{e2W\|c3XkJIF{KGGlY4XteYxifGmxbjDv[kB3cXKjbDDlcpZmdG:yZTDwdo91\WmwIIfpeIhqdiCyZYLpcpVkdGWjcjDy[Ydqd25iYYSgNk42KHWP	M4fNflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5M{[wOlc3Lz5zN{O2NFY4PjxxYU6=
U937	M2HpVmZ2dmO2aX;uJGF{e2G7	MYmxJO69VQ>?	NFzJUW0yKGh?	MXTEUXNQ	NXy5ToVoWmWmdXPld{Bj[XOjbDDUUmZidHCqYTDy[Yxm[XOnIHnuJIh2dWGwIGW5N\|ch[2WubIO=	NGOyW3A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{[4OFA6QSd-MUe2PFQxQTl:L3G+
U937	NHLQNnNHfW6ldHnvckBCe3OjeR?=	NF7rVXEyKM7:TR?=	MlHiNUBp	MnXPSG1UVw>?	M1[4UnJm\HWlZYOgUHBUNWmwZIXj[YQhXE6IYXzwbIEhemWuZXHz[UBqdiCqdX3hckBWQTN5IHPlcIx{	M37VbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5Nki0NFk6Lz5zN{[4OFA6QTxxYU6=
murine mast cell	NWDqXFRRTnWwY4Tpc44hSXO\|YYm=	M1r5R\|Eh\|ryP	MVWyOEBp	NVHJXFRmTE2VTx?=	MmfxTY5pcWKrdIOgZY51cWenbj3pcoR2[2WmIFnMOkB{\WO{ZYTpc44hcW5iSXfFJJBzcW2nZDDtc5V{\SCvYYP0JINmdGy\|IHH0JFEhfU1?	NF71NGM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{[4OFA6QSd-MUe2PFQxQTl:L3G+
FDC-P1	MXfGeY5kfGmxbjDhd5NigQ>?		MlL1OFghcHK\|		MUHJR\|UxKD1iMD6wNFc1KM7:TR?=	NHq4XIM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEG1OlY5QSd-MkCxOVY3QDl:L3G+
K562	NGraTnlEgXSxdH;4bYNqfHliYYPzZZk>		MkK3O\|IhcHK\|		NWC5SplLUUN3MDC9JFEzNjh\|IN88US=>	NHPhNJM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkKxO\|g4Pyd-MkKyNVc5Pzd:L3G+
U937	M4P4cGN6fG:2b4jpZ4l1gSCjc4PhfS=>		Mle4O\|IhcHK\|		NWXVS5l4UUN3MDC9JFE{NjZ\|IN88US=>	MoLzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ{MUe4O\|coRjJ{MkG3PFc4RC:jPh?=
Sf21	MYXGeY5kfGmxbjDhd5NigQ>?		MUW1JI1qdnN?		NWfJNHpkUUN3MDC9JFExKM7:TR?=	M17H[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OU[xOlgyLz5{Mkm2NVY5OTxxYU6=
Ba/F3	MVXGeY5kfGmxbjDhd5NigQ>?		NIG4TZcyKGi{		NWm3V2lSUW6qaXLpeIlwdiCxZjDCZ5IuSWKuIGSzNVVKKG23dHHueEApfW6tbn;3ckBwemmpaX6pJJRz[W6\|ZnXjeIVlKGmwIH3veZNmKEKjL1[zJINmdGy\|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBw\iCyaH;zdIhwenmuYYTl[EBUXEGWNTDs[ZZmdCCjZoTldkAyKGi{IHL5JHdme3Sncn6gZoxwfCCjbnHsfZNqew>?	M2HmeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NkCwPFA3Lz5{M{[wNFgxPjxxYU6=
Ba/F3	NYHsWIpETnWwY4Tpc44h[XO\|YYm=		NXyyWIRKOSCqch?=		MmTYTY5pcWKrdHnvckBw\iCEY4KtRYJtKFR\|MUXJJI12fGGwdDCoeY5sdm:5bjDvdolocW5rIITyZY5{\mWldHXkJIlvKG2xdYPlJGJiN0Z\|IHPlcIx{KGG\|c3Xzd4VlKGG\|IILl[JVkfGmxbjDv[kBxcG:\|cHjvdplt[XSnZDDDdotNKGyndnXsJIFnfGW{IEGgbJIh[nliV3XzeIVzdiCkbH;0JIFv[Wy7c3nz	Mmj4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4MEC4NFYoRjJ\|NkCwPFA3RC:jPh?=
Ba/F3	NXH1SIJoTnWwY4Tpc44h[XO\|YYm=		NWLLXFQ1OSCqch?=		MkDJTY5pcWKrdHnvckBw\iCEY4KtRYJtKFR\|MUXJJI12fGGwdDCoeY5sdm:5bjDvdolocW5rIIDoc5NxcG:{eXzheIlwdiC2cnHud4Zm[3SnZDDpckBud3W\|ZTDCZU9HOyClZXzsd{Bi\nSncjCxJIhzKGK7IGfld5Rmem5iYnzveEBidmGueYPpdy=>	NH7FV4I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[wNFgxPid-MkO2NFA5ODZ:L3G+
Sf9	NFzXbG1HfW6ldHnvckBie3OjeR?=		MonoNVUhfG9iMkCgcYlvew>?		NV\6UFhlUUN3MDC9JFE{NjFizszN	Ml7yQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN7NU[xNFEoRjJ\|OUW2NVAyRC:jPh?=
Sf9	NYrYSFJLTnWwY4Tpc44h[XO\|YYm=		M1f2bFIxKG2rboO=		M1fuOmlEPTBiPTCyO{4{KM7:TR?=	NGi0N\|I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{m1OlExOSd-MkO5OVYyODF:L3G+
HMC-1.2	NIXpO\|FCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=				MYXJR\|UxKD1iMD64NkDPxE1?	NF\Bc2c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUCwOFQxQSd-MkWwNFQ1ODl:L3G+
RXF 393NL	M3fadGFvfGmycn;sbYZmemG2aY\lJIF{e2G7		MXm0JIRigXN?		NEf3U29IUTVyIE2gNE4xOjF5IN88US=>	NX;LNIN3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwO\|YyQTVpPkK1NFc3OTl3PD;hQi=>
LXFA 983L	NX;4NZc2SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NWT5bWx6PCCmYYnz		M{HtVWdKPTBiPTCwMlA2PjVizszN	M1LvUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MEe2NVk2Lz5{NUC3OlE6PTxxYU6=
PRXF DU145	MkfCRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		M{\jdVQh\GG7cx?=		M2jkO2dKPTBiPTCwMlA3OjNizszN	M1r1ZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MEe2NVk2Lz5{NUC3OlE6PTxxYU6=
PAXF 1657L	MUfBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MlPKOEBl[Xm\|		MkX2S2k2OCB;IECuNVIyKM7:TR?=	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTB5NkG5OUc,OjVyN{[xPVU9N2F-
GXF251L	MVLBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NXPRdldKPCCmYYnz		MlTiS2k2OCB;IEKuNlUh\|ryP	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTB5NkG5OUc,OjVyN{[xPVU9N2F-
CXF 1103L	NXnRNFRnSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MoTaOEBl[Xm\|		MYDHTVUxKD1iND6zOkDPxE1?	NG\NNIE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUC3OlE6PSd-MkWwO\|YyQTV:L3G+
SH-SY5Y	NF\NT3lCeG:ydH;zbZMh[XO\|YYm=	MlrzNE4yKHWP	M4O3ZVI1KGi{cx?=		M1fB[2lv\HWldHnvckBw\iCjcH;weI9{cXNiaX6gbJVu[W5iU1itV3k2YSClZXzsd{Bie3Onc4Pl[EBieyCjY3P1cZVt[XSrb36gc4YhcHmyb3TpdIxwcWRiY3XscJMh[XRiMD6xJJVOKGGodHXyJFI1KGi{czDifUBxem:yaXTpeY0hcW:maXTlJJN1[WmwaX7nMYJie2WmIHP5eI9ndHWxcnnt[ZRzgQ>?	NIHuS5k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUS2PVc4OSd-MkW0Olk4PzF:L3G+
ECRF24	M{OybWN6fG:2b4jpZ4l1gSCjc4PhfS=>		MmrYO\|IhcHK\|		NYWyVZBSUUN3MDC9JFUvPyEQvF2=	NEj0ZYM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUixOVE2Oid-MkW4NVUyPTJ:L3G+
A2780	NXP3SIxqS3m2b4TvfIlkcXS7IHHzd4F6		NFO4fYo4OiCqcoO=		M{jDWWlEPTBiPTC4Mlch\|ryP	MlrrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6MUWxOVIoRjJ3OEG1NVUzRC:jPh?=
HEK293	M4nwUmN6fG:2b4jpZ4l1gSCjc4PhfS=>		NXLtTlA3PzJiaILz		Ml3KTWM2OCB;IEG0MlMh\|ryP	MlyxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6MUWxOVIoRjJ3OEG1NVUzRC:jPh?=
MDA-MB-231	NH7lUoZEgXSxdH;4bYNqfHliYYPzZZk>		MXi3NkBpenN?		MmjUTWM2OCB;IECuNVc5KM7:TR?=	NGfxPG09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUizOVMyPyd-MkW4N\|U{OTd:L3G+
MDA-MB-231	NHXZT4tCdnSraX72ZZNqfmViYYPzZZk>	NHP6e3AxNjFidV2=	MVWyOEBpenN?		NE\mflBCdnSraX72ZZNqfmViYXP0bZZqfHliYXfhbY5{fCCqdX3hckBOTEFvTVKtNlMyKGOnbHzzJIF1KDBwMTD1UUBi\nSncjCyOEBpenNiYomgeJJidnO5ZXzsJIF{e2G7	NYHpWXg5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4N\|U{OTdpPkK1PFM2OzF5PD;hQi=>
MDA-MB-231	NVLE[ngyS2WubDDjfYNt\SCjc4PhfS=>	MlHBNE4{KHWP	M2[2PVI1KHSxIES4JIhzew>?		MYTD[YxtKGO7Y3zlJIFzemW\|dDDpckBpfW2jbjDNSGEuVUJvMkOxJINmdGy\|IHHzd4V{e2WmIHHzJIFk[3WvdXzheIlwdiCjdDDHNE9IOSCyaHHz[UBifCByLkOgeW0h[W[2ZYKgNlQhfG9iNEigbJJ{KGK7IH\sc5ch[3m2b33leJJq[yCjbnHsfZNqew>?	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh\|NUOxO{c,OjV6M{WzNVc9N2F-
MDA-MB-231	MVfGeY5kfGmxbjDhd5NigQ>?	M3Pa[l4xNjB\|IIXN	NYKxXYpKOjBiaILz		NGPVbGxKdmirYnn0bY9vKG:oIGPyZ{BqdiCqdX3hckBOTEFvTVKtNlMyKGOnbHzzJIF{e2W\|c3XkJIF{KHKnZIXjeIlwdiCxZjDGRWsheGixc4Doc5J6dGG2aX;uJIF1KD5yLkCzJJVOKGGodHXyJFIxKGi{czDifUBY\XO2ZYLuJIJtd3RiYX7hcJl{cXN?	MonYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6M{WzNVcoRjJ3OEO1N\|E4RC:jPh?=
MDA-MB-231	NXy5W5RjSW62aX3p[5JifG:{eTDhd5NigQ>?	M1e4VVAvODNidH:gNE4{KHWP	MkLwNlAhcHK\|		MoHwRY51cW2rZ4LheI9zgSCjY4Tpeol1gSCjZ3HpcpN1KGi3bXHuJG1FSS2PQj2yN\|Eh[2WubIOgZZQhOC5yMzD0c{AxNjNidV2gZYZ1\XJiMkCgbJJ{KGK7IIfveY5lKGinYXzpcoch[XO\|YYm=	M2TufFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEO1N\|E4Lz5{NUizOVMyPzxxYU6=
MDA-MB-231	M3KwbGZ2dmO2aX;uJIF{e2G7	NILudI8xNjByMTD0c{AyKHWP	MkDhNlAhcHK\|		NF33XoFKdmirYnn0bY9vKG:oIGPyZ{BxcG:\|cHjvdplt[XSrb36gbY4hcHWvYX6gUWRCNU2ELUKzNUBk\WyuczDheEAxNjByMTD0c{AyKHWPIHHmeIVzKDJyIHjyd{BjgSCZZYP0[ZJvKGKub4SgZY5idHm\|aYO=	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh\|NUOxO{c,OjV6M{WzNVc9N2F-
MDA-MB-231	MnzMRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?	MWS+NE4xOSC3TR?=	NFjTcIkyOiCmYYnz		NXzQblh1SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvMkOxJINmdGy\|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiY3;sc456KG[xcn3heIlwdiCjdDC+NE4xOSC3TTDh[pRmeiBzMjDkZZl{KGK7IHPyfZN1[WxidnnvcIV1KHO2YXnubY5oNWKjc3XkJIF{e2G7	NHjodIo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUizOVMyPyd-MkW4N\|U{OTd:L3G+
MDA-MB-231	M3;lc2FvfGm2dX3vdkBie3OjeR?=	M1jUSFQxKG2pL3vnM4RigQ>?	NYTL[Fc{OThiZHH5dy=>		NVvmRmhWSW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gUWRCNU2ELUKzNUBk\WyuczD4[Y5w\3KjZoTl[EBqdiCVQ1nEJI1wfXOnIHHzd4V{e2WmIHHzJJR2dW:{IHfyc5d1cCCrbnjpZol1cW:wIHH0JFQxKG2pL3vnM4RigSCjZH3pcol{fGW{ZXSg[o9zKDF6IHThfZMhdWWjc4Xy[YQh\X[ncomgN{Bl[Xm\|IHT1dolv\yClb33wc5Vv\CCmb4Ppcoc>	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh\|NUOxO{c,OjV6M{WzNVc9N2F-
MDA-MB-231	M{f3bmN6fG:2b4jpZ4l1gSCjc4PhfS=>		MoD2OFghcHK\|		NHzrbXBKSzVyIE2gNU4yOiEQvF2=	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh7OUOzNkc,OjV6OUmzN\|I9N2F-
MCF7	NX;Vb45kS3m2b4TvfIlkcXS7IHHzd4F6		MXu0PEBpenN?		M3XBV2lEPTBiPTC4MlA2KM7:TR?=	NVXyRnBLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4PVk{OzJpPkK1PFk6OzN{PD;hQi=>
HCC366	MUnBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NYPvW3dxPzJiaILz		NYizdpFiUUN3MDC9JFAvODJ7IN88US=>	NX;jSGF2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xPVE{PjlpPkK2NVkyOzZ7PD;hQi=>
NCI-H2286	MlHKRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NGraVZo4OiCqcoO=		Mn;xTWM2OCB;IECuNFMzKM7:TR?=	MlXnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzOUGzOlkoRjJ4MUmxN\|Y6RC:jPh?=
K562	M1;CWWFvfGmycn;sbYZmemG2aY\lJIF{e2G7		Ml73O\|IhcHK\|		MoDVTWM2OCB;IECuNFAyKM7:TR?=	NGDKNIs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkG5OVE{Pid-Mk[xPVUyOzZ:L3G+
K562	NF6ySYVEgXSxdH;4bYNqfHliYYPzZZk>				M2HlS2lEPTBiPTCwMlA5KM7:TR?=	M{nJRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4Mk[0OVA{Lz5{NkK2OFUxOzxxYU6=
IR-K562	M1HMfWN6fG:2b4jpZ4l1gSCjc4PhfS=>				M4rTcGlEPTBiPTCxMlkh\|ryP	MnHJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ{NkS1NFMoRjJ4Mk[0OVA{RC:jPh?=
THP1	M2nx[WN6fG:2b4jpZ4l1gSCjc4PhfS=>				NXTt[\|Y4UUN3MDC9JFYh\|ryP	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjJ4NEWwN{c,OjZ{NkS1NFM9N2F-
HEK293	MnTCR5l1d3SxeHnjbZR6KGG\|c3H5				NUS1Z3R5S0N3MDC9JFE3KM7:TR?=	MorYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ{NkS1NFMoRjJ4Mk[0OVA{RC:jPh?=
K562	NFfHPVFEgXSxdH;4bYNqfHliYYPzZZk>		Mln5OFghcHK\|		MWrJR\|UxKD1iMD60OUDPxE1?	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjR3MUe3Nkc,OjZ2NUG3O\|I9N2F-
K562	MWjBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MlruO\|IhcHK\|		M17FcWdKPTBiPTCwMlAxODNizszN	NFHUSlI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nke4PVU2Oyd-Mk[3PFk2PTN:L3G+
BA/F3	M2S2cGZ2dmO2aX;uJIF{e2G7		MnfFO\|IhcHK\|		NUHWe2tST0l3MDC9JFAvODByMzFOwG0>	NFXYWZY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nke4PVU2Oyd-Mk[3PFk2PTN:L3G+
KU812	MYDBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NF;jPFM4OiCqcoO=		NHy0cIFIUTVyIE2gNE4xODB\|IN88US=>	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjd6OUW1N{c,OjZ5OEm1OVM9N2F-
MEG01	MoP3RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MmnRO\|IhcHK\|		MWDHTVUxKD1iMD6wNFA{KM7:TR?=	M3Oz[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4N{i5OVU{Lz5{Nke4PVU2OzxxYU6=
BA/F3	M3rKeWZ2dmO2aX;uJIF{e2G7		M{ex[\|czKGi{cx?=		NXS3WlJKT0l3MDC9JFAvODBzIN88US=>	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjd6OUW1N{c,OjZ5OEm1OVM9N2F-
BA/F3	Mn;BSpVv[3Srb36gZZN{[Xl?		MUW3NkBpenN?		M{PnVGdKPTBiPTCwMlAxOSEQvF2=	Mn3pQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ5OEm1OVMoRjJ4N{i5OVU{RC:jPh?=
BA/F3	M1HMe2Z2dmO2aX;uJIF{e2G7		NWDV[otTPzJiaILz		M3Xi[GdKPTBiPTCwMlAxOSEQvF2=	NVfpO5M3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[3PFk2PTNpPkK2O\|g6PTV\|PD;hQi=>
BA/F3	NH:wXJlHfW6ldHnvckBie3OjeR?=		NFXuXmg4OiCqcoO=		MoX0S2k2OCB;IECuNFA{KM7:TR?=	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjd6OUW1N{c,OjZ5OEm1OVM9N2F-
BA/F3	MmfjSpVv[3Srb36gZZN{[Xl?		MYS3NkBpenN?		M1n5OWdKPTBiPTCwMlAxOyEQvF2=	NVzaRZlVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[3PFk2PTNpPkK2O\|g6PTV\|PD;hQi=>
BA/F3	MVrGeY5kfGmxbjDhd5NigQ>?		NH3Odpo4OiCqcoO=		M2fhbmdKPTBiPTCwMlAxOyEQvF2=	M{fFd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4N{i5OVU{Lz5{Nke4PVU2OzxxYU6=
BA/F3	NYf6TWpnTnWwY4Tpc44h[XO\|YYm=		NIPYNIo4OiCqcoO=		NIjHdnRIUTVyIE2gNE4xODNizszN	M3uxPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4N{i5OVU{Lz5{Nke4PVU2OzxxYU6=
BA/F3	MXrGeY5kfGmxbjDhd5NigQ>?		M13ZcFczKGi{cx?=		M33hO2dKPTBiPTCwMlAxPCEQvF2=	M3P4dlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4N{i5OVU{Lz5{Nke4PVU2OzxxYU6=
BA/F3	NFu4cZhHfW6ldHnvckBie3OjeR?=		NIj1O2c4OiCqcoO=		MXrHTVUxKD1iMD6wNFQh\|ryP	M{\RVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4N{i5OVU{Lz5{Nke4PVU2OzxxYU6=
BA/F3	NHy0UWdHfW6ldHnvckBie3OjeR?=		MmfyO\|IhcHK\|		Mkm4S2k2OCB;IECuNFA2KM7:TR?=	MojOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ5OEm1OVMoRjJ4N{i5OVU{RC:jPh?=
BA/F3	NV;ye3hyTnWwY4Tpc44h[XO\|YYm=		M{O2UlczKGi{cx?=		MnXjS2k2OCB;IECuNFA5KM7:TR?=	Ml:5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ5OEm1OVMoRjJ4N{i5OVU{RC:jPh?=
BA/F3	MX\GeY5kfGmxbjDhd5NigQ>?		M1PsOFczKGi{cx?=		NF7ZOnFIUTVyIE2gNE4xODhizszN	MkH4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ5OEm1OVMoRjJ4N{i5OVU{RC:jPh?=
BA/F3	MVjGeY5kfGmxbjDhd5NigQ>?		MlXWO\|IhcHK\|		NUXNZnNvT0l3MDC9JFAvODFizszN	NFG1coU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nke4PVU2Oyd-Mk[3PFk2PTN:L3G+
BA/F3	NVLIbFdmTnWwY4Tpc44h[XO\|YYm=		M1\S[FczKGi{cx?=		NWn1fFhjT0l3MDC9JFAvODF2IN88US=>	NG\PNlk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nke4PVU2Oyd-Mk[3PFk2PTN:L3G+
BA/F3	NFnTeGZHfW6ldHnvckBie3OjeR?=		M2DxblczKGi{cx?=		NGnGUpJIUTVyIE2gNE4xOTRizszN	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjd6OUW1N{c,OjZ5OEm1OVM9N2F-
BA/F3	MnjMSpVv[3Srb36gZZN{[Xl?		NILjS3o4OiCqcoO=		M{LTc2dKPTBiPTCwMlAyPyEQvF2=	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjd6OUW1N{c,OjZ5OEm1OVM9N2F-
BA/F3	MlHBSpVv[3Srb36gZZN{[Xl?		M3XFdVczKGi{cx?=		MXPHTVUxKD1iMD6wN\|kh\|ryP	NV;GV2h6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[3PFk2PTNpPkK2O\|g6PTV\|PD;hQi=>
CHL	NH;XWJRCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NGnpUpg4OiCqcoO=		Mnf4S2k2OCB;IECuNlch\|ryP	M3HjVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4N{i5OVU{Lz5{Nke4PVU2OzxxYU6=
MOLM14	NG[5T5hCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MYS3NkBpenN?		NV7O[3JlT0l3MDC9JFIvOyEQvF2=	MkSyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ5OEm1OVMoRjJ4N{i5OVU{RC:jPh?=
BA/F3	NXe2cnI1TnWwY4Tpc44h[XO\|YYm=		MXO3NkBpenN?		M{eyUmdKPTBiPTCzJO69VQ>?	M4GxZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4N{i5OVU{Lz5{Nke4PVU2OzxxYU6=
BA/F3	Mom5SpVv[3Srb36gZZN{[Xl?		M2n2XlczKGi{cx?=		NF3nUlVIUTVyIE2gN{DPxE1?	M2TDc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4N{i5OVU{Lz5{Nke4PVU2OzxxYU6=
MV4-11	MVnBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NGro[YI4OiCqcoO=		NX3IW4J7T0l3MDC9JFMvPiEQvF2=	NVfoPIh{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[3PFk2PTNpPkK2O\|g6PTV\|PD;hQi=>
HEL	NYDKfFZXSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		M3HmPFczKGi{cx?=		NHmxVZlIUTVyIE2gOU4{KM7:TR?=	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjd6OUW1N{c,OjZ5OEm1OVM9N2F-
BA/F3	M4KyPWZ2dmO2aX;uJIF{e2G7		MV:3NkBpenN?		NFXacmhIUTVyIE2gPU46PCEQvF2=	M{DNcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4N{i5OVU{Lz5{Nke4PVU2OzxxYU6=
KU812	NH;sbZZHfW6ldHnvckBie3OjeR?=	M1fqSlAvOSC3TR?=	M3TxdFEhcHJ?		NIPhdpBKdmirYnn0bY9vKG:oIFLDVk9CSkxiaX6gbJVu[W5iS2W4NVIh[2WubIOgZZN{\XO\|ZXSgZZMh\G:5boLl[5Vt[XSrb36gc4YhS3KtTDDwbI9{eGixconsZZRqd25iYYSgWFIxPyC\|aYTlJIF1KDBwMTD1UUBi\nSncjCxJIhzKGK7IHntcZVvd2Kub4T0bY5oKG2ndHjv[C=>	NIm4SXI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nke4PVU2Oyd-Mk[3PFk2PTN:L3G+
KU812	NHr2OHlHfW6ldHnvckBie3OjeR?=	MXewMlEhfU1?	NGTLRmgyKGi{		M13uOWlvcGmkaYTpc44hd2ZiQlPSM2FDVCCrbjDoeY1idiCNVUixNkBk\WyuczDhd5Nme3OnZDDhd{Bld3ewcnXneYxifGmxbjDv[kBEemuOIIDoc5NxcG:{eXzheIlwdiCjdDDUNlA4KHOrdHWgZZQhOC5zIIXNJIFnfGW{IEGgbJIh[nliaX3teY5w[myxdITpcochdWW2aH;k	MomzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ5OEm1OVMoRjJ4N{i5OVU{RC:jPh?=
MEG01	M4fuSWZ2dmO2aX;uJIF{e2G7	MoTENE4yKHWP	M13QTVEhcHJ?		M3;FSGlvcGmkaYTpc44hd2ZiQlPSM2FDVCCrbjDoeY1idiCPRVewNUBk\WyuczDhd5Nme3OnZDDhd{Bld3ewcnXneYxifGmxbjDv[kBEemuOIIDoc5NxcG:{eXzheIlwdiCjdDDUNlA4KHOrdHWgZZQhOC5zIIXNJIFnfGW{IEGgbJIh[nliaX3teY5w[myxdITpcochdWW2aH;k	M33DNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4N{i5OVU{Lz5{Nke4PVU2OzxxYU6=
MEG01	Mn;QSpVv[3Srb36gZZN{[Xl?	MnjaNE4yKHWP	NF\XT40yKGi{		NWDWU2dUUW6qaXLpeIlwdiCxZjDCR3IwSUKOIHnuJIh2dWGwIF3FS\|AyKGOnbHzzJIF{e2W\|c3XkJIF{KGSxd37y[Yd2dGG2aX;uJI9nKEO{a1ygdIhwe3Cqb4L5cIF1cW:wIHH0JHQzODdic3n0[UBifCByLkGgeW0h[W[2ZYKgNUBpeiCkeTDpcY12dm:kbH;0eIlv\yCvZYToc4Q>	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjd6OUW1N{c,OjZ5OEm1OVM9N2F-
K562	NVvYZYc5TnWwY4Tpc44h[XO\|YYm=	NUfJbGNROC5zIIXN	MYKxJIhz		NXjY[\|U{UW6qaXLpeIlwdiCxZjDCR3IwSUKOIHnuJIh2dWGwIFu1OlIh[2WubIOgZZN{\XO\|ZXSgZZMh\G:5boLl[5Vt[XSrb36gc4YhS3KtTDDwbI9{eGixconsZZRqd25iYYSgWFIxPyC\|aYTlJIF1KDBwMTD1UUBi\nSncjCxJIhzKGK7IHntcZVvd2Kub4T0bY5oKG2ndHjv[C=>	MmnmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ5OEm1OVMoRjJ4N{i5OVU{RC:jPh?=
K562	M3e3ZmZ2dmO2aX;uJIF{e2G7	NFPvU4wxNjFidV2=	MmrBNUBpeg>?		M4jZNGlvcGmkaYTpc44hd2ZiQlPSM2FDVCCrbjDoeY1idiCNNU[yJINmdGy\|IHHzd4V{e2WmIHHzJIRwf26{ZXf1cIF1cW:wIH;mJGNzc0xicHjvd5Bpd3K7bHH0bY9vKGG2IGSyNFche2m2ZTDheEAxNjFidV2gZYZ1\XJiMTDodkBjgSCrbX31co9jdG:2dHnu[{Bu\XSqb3S=	MmnsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ5OEm1OVMoRjJ4N{i5OVU{RC:jPh?=
K562	NFq5SIFEgXSxdH;4bYNqfHliYYPzZZk>		NFfOcVE4OiCqcoO=		MYrJR\|UxKD1iMD6wNFAzPSEQvF2=	M{DZNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4OEG0PFkxLz5{NkixOFg6ODxxYU6=
BA/F3	M4XZU2N6fG:2b4jpZ4l1gSCjc4PhfS=>		MlL5O\|IhcHK\|		MWLJR\|UxKD1iMD6wPUDPxE1?	MlnNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ6MUS4PVAoRjJ4OEG0PFkxRC:jPh?=
BAF3	M2f1fmZ2dmO2aX;uJIF{e2G7		M3v6XlczKGi{cx?=		NYX6VXJsTUN3MDC9JFAvODByMESg{txO	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzBzMEixNEc,OjdyMUC4NVA9N2F-
BAF3	MWDGeY5kfGmxbjDhd5NigQ>?		Mn:5O\|IhcHK\|		MmHQSWM2OCB;IECuNFAxODRizszN	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzBzMEixNEc,OjdyMUC4NVA9N2F-
BxPC3	M1\keGFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NHTMe5A4OiCqcoO=		MlfGSWM2OCB;IECuNFM{KM7:TR?=	NUjXV5RNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkewNVA5OTBpPkK3NFExQDFyPD;hQi=>
MDA-MB-231	MmrPRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		Mn7EO\|IhcHK\|		MXvFR\|UxKD1iMD6wOFQh\|ryP	NHzKd2o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{CxNFgyOCd-MkewNVA5OTB:L3G+
Caki2	Mo\3RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		M3jXN\|czKGi{cx?=		MXXFR\|UxKD1iMD6wOVUh\|ryP	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzBzMEixNEc,OjdyMUC4NVA9N2F-
NCI-H1975	MXjBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		M2q0S\|czKGi{cx?=		MnTZSWM2OCB;IECuNVc{KM7:TR?=	NEL5OY89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{CxNFgyOCd-MkewNVA5OTB:L3G+
PC3	Mn;BRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MYq3NkBpenN?		Mn;vSWM2OCB;IECuNlMzKM7:TR?=	M{HnPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MEGwPFExLz5{N{CxNFgyODxxYU6=
insect	MmHaSpVv[3Srb36gZZN{[Xl?		NXSxcnE3OjBibXnudy=>		M4fSb2lEPTBiPTCwMlAxODVizszN	M13Kd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MUG1PFM2Lz5{N{GxOVg{PTxxYU6=
MDA-MB-231	NIHIUXFCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		Mn;IOUBl[Xm\|		MXrBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2GQT3NRk0zOzFiY3XscJMh[XO\|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJINmdGxidnnhZoltcXS7IHHmeIVzKDViZHH5d{BjgSCScnXzeI9DdHWnIHHzd4F6	M2iwNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MUG1PFM2Lz5{N{GxOVg{PTxxYU6=
MDA-MB-231	MkXHSpVv[3Srb36gZZN{[Xl?	M{m4[VMhfG9iMUCwJI5O	NYTzdHhmOS53IHjydy=>		NWKwfFBJUW6qaXLpeIlwdiCxZjDTVmMheGixc4Doc5J6dGG2aX;uJIF1KHS7cn;zbY5mKDRzNjDpckBpfW2jbjDNSGEuVUJvMkOxJINmdGy\|IHH0JFMhfG9iMUCwJI5OKHC{ZXnuZ5Vj[XSnZDDmc5IhOS53IHjyd{Bnd2yub4fl[EBjgSC\|ZYL1cUB{fGmvdXzheIlwdiCob4KgNUBpeiCkeTDX[ZN1\XKwIHLsc5Qh[W6jbInzbZM>	NIq1bXk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{GxOVg{PSd-MkexNVU5OzV:L3G+
MDA-MB-231	M2jIRWZ2dmO2aX;uJIF{e2G7	NIS1fVY{KHSxIEGwNEBvVQ>?	NH;1e5oyNjViaILz		M1vBXGlvcGmkaYTpc44hd2ZiRlHLJJBpd3OyaH;yfYxifGmxbjDheEB1gXKxc3nu[UA5PjFiaX6gbJVu[W5iTVTBMW1DNTJ\|MTDj[YxteyCjdDCzJJRwKDFyMDDuUUBxemWrbnP1ZoF1\WRiZn;yJFEvPSCqcoOg[o9tdG:5ZXSgZpkhe2W{dX2gd5RqdXWuYYTpc44h\m:{IEGgbJIh[nliV3XzeIVzdiCkbH;0JIFv[Wy7c3nz	NYq0Omo{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkexNVU5OzVpPkK3NVE2QDN3PD;hQi=>
MDA-MB-231	MUjBcpRqdWmpcnH0c5J6KGG\|c3H5	NIjmTFkyOCCwTR?=	MVm2JIhzew>?		M2\0bWFvfGmvaXfyZZRwenliYXP0bZZqfHliaX6gbJVu[W5iTVTBMW1DNTJ\|MTDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4h[2WubDDtc5RqdGm2eTDheEAyOCCwTTDheEA3KGi{czDifUBucWO{b4Pjc5B6KGKjc3XkJJNkemG2Y3ite492dmRiY3XscEBucWe{YYTpc44h[XO\|YYm=	M2T0cFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MUG1PFM2Lz5{N{GxOVg{PTxxYU6=
MCF7	M2PoNWFvfGmycn;sbYZmemG2aY\lJIF{e2G7	NFjMV5AxNjB\|IITvJFMxOCC3TR?=	M4\2[\|Uh\GG7cx?=		Ml3sRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPQ1[3JINmdGy\|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiClZXzsJJZq[WKrbHn0fUBifCByLkCzJJRwKDNyMDD1UUBi\nSncjC1JIRigXNiYomgVJJme3SxQnz1[UBie3OjeR?=	NYTqPHBWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkexNVU5OzVpPkK3NVE2QDN3PD;hQi=>
HCT116	NYLITIpNS3m2b4TvfIlkcXS7IHHzd4F6		NXLhOlcxQTZiaILz		M4P5emlEPTBiPTC1MlI{KM7:TR?=	MlOwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdzNUW0OlQoRjJ5MUW1OFY1RC:jPh?=
A549	M13SXWN6fG:2b4jpZ4l1gSCjc4PhfS=>		M4DVbVk3KGi{cx?=		NYfLeGptUUN3MDC9JFgvOzdizszN	NILu[o49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{G1OVQ3PCd-MkexOVU1PjR:L3G+
U937	MWnDfZRwfG:6aXPpeJkh[XO\|YYm=		NV7oPGVDQTZiaILz		M3vZUWlEPTBiPTCxNE4zOyEQvF2=	M1XrSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MUW1OFY1Lz5{N{G1OVQ3PDxxYU6=
K562	M1;XcmN6fG:2b4jpZ4l1gSCjc4PhfS=>		M1PBfFk3KGi{cx?=		NFHsd5FKSzVyIE2gNVEvQTVizszN	NXzxfHRMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkexOVU1PjRpPkK3NVU2PDZ2PD;hQi=>
K562	MVPDfZRwfG:6aXPpeJkh[XO\|YYm=				NYj0SWYzS0N3MDC9JFAvOjVizszN	NGLTUXI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{S3OFkyQCd-Mke0O\|Q6OTh:L3G+
K562	MWTBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?				NITQeHpIUTVyIE2gNE4xODFizszN	M{PzTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NEO1OVI3Lz5{OESzOVUzPjxxYU6=
K562	NGGyb3RHfW6ldHnvckBie3OjeR?=				M2niVGlEPTBiPTCwMlAxODB4OTFOwG0>	NVPVNGJrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmzPVU6PzNpPkK5N\|k2QTd\|PD;hQi=>
HL60	NYrxRpVyTnWwY4Tpc44h[XO\|YYm=				MUnJR\|UxKD1iMD6wNFAyOSEQvF2=	NH[xSnk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUO5OVk4Oyd-MkmzPVU6PzN:L3G+
KG1a	MnztSpVv[3Srb36gZZN{[Xl?				NUjOeIhLUUN3MDC9JFgvQThizszN	NVnkTGNjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmzPVU6PzNpPkK5N\|k2QTd\|PD;hQi=>
B16-BL6	NXfzN4dqTnWwY4Tpc44h[XO\|YYm=	NV20[oFlQC5zMzD1US=>	MnS2NlQhfG9iNEigbJJ{		NV\pOW9GUW6qaXLpeIlwdiCxZjDj[YxtKG2rZ4LheIlwdiCxZjDtc5V{\SCEMU[tRmw3KGOnbHzzJIF1KDhwMUOgeW0hcW6ldXLheIVlKG[xcjCyOEB1dyB2ODDodpMh[nliY3XscEB4d3WwZDDzZ5JifGOqIHHzd4F6	Ml31QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl\|OUW5O\|MoRjJ7M{m1PVc{RC:jPh?=
MCF7	NIjINopHfW6ldHnvckBie3OjeR?=	MVO3MlUhfU1?	NYq5RY9tOTBiZHH5dy=>		M{P5PWlvcGmkaYTpc44hd2ZiY3;sc456KG[xcn3heIlwdiCrbjDoeY1idiCPQ1[3JINmdGy\|IHH0JFcvPSC3TTDpcoN2[mG2ZXSg[o9zKDFyIHThfZMh[nliY4L5d5RidCC4aX;s[ZQhe3SjaX7pcoch[mG\|ZXSgdIxifGViY3zvcolv\yC2ZYP0	NWCwSlJNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmzPVU6PzNpPkK5N\|k2QTd\|PD;hQi=>
U-2 OS	M1LEeZFJXFNiYYPzZZk>				NUT6cHdueUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGWtNkBQWyClZXzsdy=>	M3\PZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
A673	NVjR[ndoeUiWUzDhd5NigQ>?				MnX4dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKEF4N{OgZ4VtdHN?	MoTnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
DAOY	NYK5e\|VHeUiWUzDhd5NigQ>?				MoDldWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKESDT2mgZ4VtdHN?	M1HXS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
MG 63 (6-TG R)	MnvUdWhVWyCjc4PhfS=>				NXTCN3NueUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IF3HJFY{KCh4LWTHJHIqKGOnbHzz	M1:zRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
OHS-50	NW\J[ohreUiWUzDhd5NigQ>?				NIP3UYZyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiT1jTMVUxKGOnbHzz	NETUZ3A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
BT-12	M4jlXpFJXFNiYYPzZZk>				NI\5ZZVyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBDXC1zMjDj[Yxtew>?	NHfHRng9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
DAOY	NV[4fVJleUiWUzDhd5NigQ>?				M3mxbZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJGRCV1liY3XscJM>	MmrmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
SK-N-SH	NVjxfGpjeUiWUzDhd5NigQ>?				MXvxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDTT{1PNVOKIHPlcIx{	NGjDXo49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
A673	MX3xTHRUKGG\|c3H5				MX3xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDBOlc{KGOnbHzzLS=>	Mlu1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
Rh30	NV\RSIVSeUiWUzDhd5NigQ>?				M1WxcJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHJpOzBiY3XscJM>	NInBbnc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
U-2 OS	MlvpdWhVWyCjc4PhfS=>				NVXseY9QeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhXS1{IF;TJINmdGy\|	NHTOT2E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
Rh41	MYfxTHRUKGG\|c3H5				Mn\rdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgVog1OSClZXzsdy=>	MnjkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
SJ-GBM2	M{POfZFJXFNiYYPzZZk>				NIS5PFhyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1qtS2JOOiClZXzsdy=>	MoexQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
SK-N-MC	M2f2fZFJXFNiYYPzZZk>				NEnDNGpyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1utUk1OSyClZXzsdy=>	M4jxVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh18	NHK5[\|RyUFSVIHHzd4F6				Ml\KdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKqMUigZ4VtdHN?	NH;DPVc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
Rh18	MU\xTHRUKGG\|c3H5				MkTJdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgVogyQCClZXzsdy=>	MnmzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
HEK293	NU\xPJBXTnWwY4Tpc44h[XO\|YYm=		MnTwNUBpeg>?		M1zu[mtqKD1iMD6wNFA2KM7:TR?=	NYfHdYFiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm5OFEyQTNpPkK5PVQyOTl\|PD;hQi=>
HEK293	Ml;DSpVv[3Srb36gZZN{[Xl?		MoHMNUBpeg>?		M4rRU2lEPTBiPTCwMlAxPiEQvF2=	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTl2MUG5N{c,Ojl7NEGxPVM9N2F-
Ba/F3	NYGwRpBNTnWwY4Tpc44h[XO\|YYm=		MYm0PEBpenN?		NXnZcGU1T0l3MDC9JFAvODByMkGg{txO	M4DkelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMUO3PVgyLz5\|MEGzO\|k5OTxxYU6=
Ba/F3	M3P5eWZ2dmO2aX;uJIF{e2G7		NI\wOY81QCCqcoO=		NHjIO5JIUTVyIE2gNE4xODB{NTFOwG0>	MoHrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzBzM{e5PFEoRjNyMUO3PVgyRC:jPh?=
Ba/F3	NHv5Z3dHfW6ldHnvckBie3OjeR?=		NYnlWFM5PDhiaILz		MXPHTVUxKD1iMD6wNFAzQSEQvF2=	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODF\|N{m4NUc,OzBzM{e5PFE9N2F-
Ba/F3	MULGeY5kfGmxbjDhd5NigQ>?		NGXVZoY1QCCqcoO=		MnWyS2k2OCB;IECuNFAxOyEQvF2=	NHfPcpM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEGzO\|k5OSd-M{CxN\|c6QDF:L3G+
Ba/F3	NGLBZpdHfW6ldHnvckBie3OjeR?=		NETQNFg1QCCqcoO=		MoHYS2k2OCB;IECuNFAxOzNizszN	MmHmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzBzM{e5PFEoRjNyMUO3PVgyRC:jPh?=
Ba/F3	MnLRSpVv[3Srb36gZZN{[Xl?		MnHCOFghcHK\|		MUDHTVUxKD1iMD6wNFA1OiEQvF2=	NUX3SItWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CxN\|c6QDFpPkOwNVM4QThzPD;hQi=>
Ba/F3	MmPQSpVv[3Srb36gZZN{[Xl?		NFHyNlc1QCCqcoO=		MXjHTVUxKD1iMD6wNFA4PyEQvF2=	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODF\|N{m4NUc,OzBzM{e5PFE9N2F-
Ba/F3	NFHYZXdHfW6ldHnvckBie3OjeR?=		NFrGfHU1QCCqcoO=		M2DkSGdKPTBiPTCwMlAxODl6IN88US=>	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODF\|N{m4NUc,OzBzM{e5PFE9N2F-
Ba/F3	NXuyO5oxTnWwY4Tpc44h[XO\|YYm=		M2e4Z\|Q5KGi{cx?=		MXPHTVUxKD1iMD6wNFE1PCEQvF2=	M4noU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMUO3PVgyLz5\|MEGzO\|k5OTxxYU6=
Ba/F3	NYTK[5NnTnWwY4Tpc44h[XO\|YYm=		NGTTZmI1QCCqcoO=		MWjHTVUxKD1iMj61OlIh\|ryP	NHvKcYo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEGzO\|k5OSd-M{CxN\|c6QDF:L3G+
Vero	M3PCS5FJXFNiYYPzZZk>				M1rvWXZmem9iY3XscJMhfmmjYnnsbZR6KHGKVGOg[o9zKFqra3GgeolzfXNiaX7obYJqfG:{cx?=	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{OzJ{OUW0OUc,OzN{Mkm1OFU9N2F-
HepG2	MkD6dWhVWyCjc4PhfS=>				NETLfpRJ\XCJMjDj[YxteyC4aXHibYxqfHlicVjUV{Bnd3JiWnnrZUB3cXK3czDpcohq[mm2b4Lz	NV3HVW9oRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{OyNlk2PDVpPkOzNlI6PTR3PD;hQi=>
BV-173	M1zHUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmW4TWM2OD1yLkCwNFAxODFyOTFOwG0>	M2XZdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
K-562	NUnySldHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUTJR\|UxRTBwMECwNFAxOjZ4IN88US=>	M1PGVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
BL-70	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUPtXJp7UUN3ME2wMlAxODByMEiyNkDPxE1?	NYfW[\|g1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
EM-2	MmXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlnlTWM2OD1yLkCwNFAxOTB6IN88US=>	Mne5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
LAMA-84	NUDNUXBqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHLzPFBKSzVyPUCuNFAxODB\|MkGg{txO	NHXLSJk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
MEG-01	NHzHRpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVHJR\|UxRTBwMECwNFA6QCEQvF2=	NYXTSIxvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
EoL-1-cell	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXrjTmhmUUN3ME2wMlAxODBzM{Gg{txO	NGn5OJk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
CTV-1	NYPBOYtvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWex[nRYUUN3ME2wMlAxODB2MESg{txO	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
TE-15	M1\SS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIXu[mZKSzVyPUCuNFA2QDlizszN	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
NOS-1	Mn3kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVzJR\|UxRTBwMEC2NVMh\|ryP	MnrtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
D-336MG	NIjuVFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M37qO2lEPTB;MD6wNFY{KM7:TR?=	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
LB1047-RCC	NITYc3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGrVU25KSzVyPUCuNFA6QDlizszN	M3rTblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
LB996-RCC	NXztO2Z2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGW0WWRKSzVyPUCuNFA6QTFizszN	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
SW982	Ml\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M13rSGlEPTB;MD6wNVEyPSEQvF2=	MkPxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
TK10	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIixPJpKSzVyPUCuNFEyPzRizszN	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
A704	NHP1Nm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVnJR\|UxRTBwMEG0PVEh\|ryP	NEL1OoU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
TE-8	M4[yW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2\yO2lEPTB;MD6wNVU4PiEQvF2=	NFLaTXY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
DOHH-2	Mn3aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{LUO2lEPTB;MD6wNVcyQSEQvF2=	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
HOP-62	M3PidWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYrJR\|UxRTBwMEG4N\|Qh\|ryP	NIHlR3g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
TE-12	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV3RRnhHUUN3ME2wMlAyQDZzIN88US=>	NH3ifXM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
KGN	M3;uTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4nXWmlEPTB;MD6wNVk1OiEQvF2=	M2i2W\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
NCI-H1648	M1HPPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV\BSoxQUUN3ME2wMlAzODFzIN88US=>	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
OS-RC-2	MojsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3yzR2lEPTB;MD6wNlA{KM7:TR?=	MmjpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
GB-1	NFnTXWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIG5fZJKSzVyPUCuNFIyPTdizszN	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
RXF393	MlXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2G4[WlEPTB;MD6wNlM2PyEQvF2=	NYLWfGxVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
LC-2-ad	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1rQe2lEPTB;MD6wNlU5PiEQvF2=	M1rk[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
KS-1	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoiyTWM2OD1yLkCyO\|Mh\|ryP	NF23UYc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
ETK-1	NHm1PHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYfJR\|UxRTBwMEK4N\|Ih\|ryP	NEfEU\|k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
SW954	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml34TWM2OD1yLkCyPVI4KM7:TR?=	Ml;2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
Becker	NHLZ[pJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHnN[mZKSzVyPUCuNFMxODNizszN	NVHIb29RRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
MZ1-PC	NHSwUZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWL3OFVJUUN3ME2wMlA{OTF7IN88US=>	Mo\kQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
ES6	NHz4UHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYnJR\|UxRTBwMEOxPVMh\|ryP	NG\iZZM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
KURAMOCHI	NH\CXZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWnZW2dJUUN3ME2wMlA{PDh5IN88US=>	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
CGTH-W-1	MnzrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3fUVWlEPTB;MD6wN\|U1QCEQvF2=	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
VA-ES-BJ	NWDnVGpJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{DuU2lEPTB;MD6wN\|kxOiEQvF2=	M3nofVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
LXF-289	MofDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkPiTWM2OD1yLkCzPVU3KM7:TR?=	M3;zdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
MPP-89	M3HGcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVrm[nc2UUN3ME2wMlA1ODR7IN88US=>	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
SW872	M1HiZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYPJR\|UxRTBwMESxOlEh\|ryP	NUnoboJHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
SNB75	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYXOR25[UUN3ME2wMlA1PDN3IN88US=>	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
PSN1	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4f4b2lEPTB;MD6wOFQ4PCEQvF2=	M{TYW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
LB831-BLC	NWXuUZdQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4HiNGlEPTB;MD6wOFYxQSEQvF2=	NIL1Xno9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
MFH-ino	M1n5PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn7UTWM2OD1yLkC0O\|I1KM7:TR?=	M{TQO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
TGBC24TKB	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M365N2lEPTB;MD6wOFc3OSEQvF2=	MmXZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
A388	NE\Sb\|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Moi0TWM2OD1yLkC1NFk2KM7:TR?=	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
BB30-HNC	MkTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2Dh[WlEPTB;MD6wOVQ{PyEQvF2=	NWTFfIdjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
GI-ME-N	NInSS3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M164TWlEPTB;MD6wOlEyQCEQvF2=	NE\KTGQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
TGBC1TKB	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHGy[ZlKSzVyPUCuNFYyPjRizszN	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
TE-10	MlfvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3;HdGlEPTB;MD6wOlM2PyEQvF2=	MmL4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
A498	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlrFTWM2OD1yLkC3Nlg1KM7:TR?=	NHXtO2s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
TE-11	M2PRb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3zrcWlEPTB;MD6wO\|g2QCEQvF2=	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
BB65-RCC	NHP0W2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1zZdmlEPTB;MD6wPFIzPyEQvF2=	MnL0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
C2BBe1	MljFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1PGOWlEPTB;MD6wPFMxQCEQvF2=	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
NCI-H747	M4PkPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIHFOlZKSzVyPUCuNFg{PjJizszN	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
IST-MES1	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnHrTWM2OD1yLkC4OVUzKM7:TR?=	NF;HUIQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
KALS-1	MlTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVTzXoZGUUN3ME2wMlA6PDlizszN	NYTqTVJvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
GCIY	NUCwbVZWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnfpTWM2OD1yLkC5OlU3KM7:TR?=	NXnVbZBkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
RL95-2	MmrmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXrJR\|UxRTBwMUCzPEDPxE1?	NFe5SXc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
TE-1	NFrRXnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX;JR\|UxRTBwMUC1OEDPxE1?	MkjDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
NCI-H1355	M{K5dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUS2NGRmUUN3ME2wMlEyODJ6IN88US=>	NU\WRY1oRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
SW962	NVrUZlFOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH7kOVBKSzVyPUCuNVEzQTJizszN	NVfxU5ZORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
KLE	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYjJR\|UxRTBwMUGzNVch\|ryP	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
MC116	NVHFcXFiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXfJR\|UxRTBwMUG0NUDPxE1?	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
NMC-G1	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWXJR\|UxRTBwMUG2NFYh\|ryP	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
KU812	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGf1SVVKSzVyPUCuNVE5QDNizszN	NGH4cVk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
COLO-829	NYrORZRWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn33TWM2OD1yLkGyNlE{KM7:TR?=	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
NTERA-S-cl-D1	NWr1co5LT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NED2OFJKSzVyPUCuNVIzQDNizszN	M4fzeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
IST-MEL1	M{TCfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYPJR\|UxRTBwMUO0OUDPxE1?	NHntZlk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
MLMA	Mlm3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3rS[2lEPTB;MD6xOFA{OiEQvF2=	NVfKc3BXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
LS-123	MlrHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{PUWGlEPTB;MD6xOFA3PCEQvF2=	M17hbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
LB2518-MEL	NYfrdVNOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGLLbYVKSzVyPUCuNVQyPjJizszN	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
NB69	M1vvZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmHYTWM2OD1yLkG0OFM3KM7:TR?=	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
8-MG-BA	NHTySFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1Hj[mlEPTB;MD6xOVQ2QCEQvF2=	NIHLbpQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
K5	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYnqR3h1UUN3ME2wMlE3PDh7IN88US=>	NGnubYc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
KINGS-1	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV7JR\|UxRTBwMU[2OlYh\|ryP	M{LJelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
SF268	MkHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MULJR\|UxRTBwMUe0NFQh\|ryP	MmCxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
PF-382	NILkWYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlHXTWM2OD1yLkG3Olc5KM7:TR?=	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
SH-4	MorrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFjneohKSzVyPUCuNVg1OTNizszN	NVv2N5I{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
NALM-6	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYHJR\|UxRTBwMUmyPVUh\|ryP	NWDnWWhQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
CP66-MEL	NHjaWHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWCxbXhxUUN3ME2wMlE6PTNzIN88US=>	M3vINFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
697	M4X0UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFTDeWVKSzVyPUCuNVk6QDdizszN	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
CP67-MEL	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{[ydmlEPTB;MD6yNFQ5QCEQvF2=	M4TIcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
DSH1	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NY[wR5ZLUUN3ME2wMlI1ODBzIN88US=>	M3PSUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
HCE-4	NFPxfldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NED3[XRKSzVyPUCuNlY1OzlizszN	NYr6dHdSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
MZ2-MEL	NIOyTIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml;LTWM2OD1yLkK4OVM4KM7:TR?=	Ml3DQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
BL-41	NF7BSG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXLIbpB4UUN3ME2wMlI6OTJ\|IN88US=>	NFG4R\|c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
HUTU-80	Ml7xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVHJR\|UxRTBwM{G0NkDPxE1?	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
LOXIMVI	NVjiXYhGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWf4N4R7UUN3ME2wMlMyPTB\|IN88US=>	NEX1Z4g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
no-10	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlW0TWM2OD1yLkOxPVMyKM7:TR?=	NW\3ToF7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
KARPAS-422	NXfleIpYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHf0RpRKSzVyPUCuN\|M6QTdizszN	NX7XU4NqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
SW684	NGSzbFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4X0W2lEPTB;MD6zOFk5KM7:TR?=	Ml3mQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
SF126	NELCWJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlTRTWM2OD1yLkO1OFEh\|ryP	M1:xWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
D-263MG	NW\ROFl4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlTZTWM2OD1yLkO2NlI1KM7:TR?=	NXPrXYV7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
OVCAR-4	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGjFPG9KSzVyPUCuN\|c1OzNizszN	M1HJWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
BB49-HNC	M{TsNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{O4PGlEPTB;MD6zPFU6QSEQvF2=	MkLhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
ONS-76	NF72NWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoLUTWM2OD1yLkSyPVUyKM7:TR?=	NVvWNmlERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
MZ7-mel	NWW0S\|hbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHT0dJFKSzVyPUCuOFc6OTFizszN	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
RCC10RGB	NHjDR5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3v5UWlEPTB;MD60PVEyKM7:TR?=	MlfGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
BOKU	NYjSUJJyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYLJR\|UxRTBwNEmxN\|Mh\|ryP	MlywQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
no-11	NWrqfVFRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWfJR\|UxRTBwNUCyNlgh\|ryP	M3jWVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
IST-SL2	NW\P[GF4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4T2[2lEPTB;MD61NFMxOiEQvF2=	M2\BcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
RKO	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1rn[mlEPTB;MD61Nlk3PiEQvF2=	MoCzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
HT-144	NH;ScHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVLJR\|UxRTBwNUO2NFkh\|ryP	NFvEPHE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
NCI-H446	NHLINplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX3MVIVDUUN3ME2wMlYzPzZizszN	NVv5bWVFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
QIMR-WIL	NUTsW2MxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXrQR4NLUUN3ME2wMlcxPjJ7IN88US=>	NX\rT\|ltRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
MHH-PREB-1	NEnHUpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX7qU2w4UUN3ME2wMlc1PDZ7IN88US=>	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
EW-16	NV3QUGtbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX;JR\|UxRTBwN{[xO\|gh\|ryP	NF\Jd3U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
EW-24	NGL6TY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF22eo1KSzVyPUCuO\|gyPjVizszN	Mlj1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
LB373-MEL-D	M2\Oc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYD3[2hOUUN3ME2wMlgzPTB6IN88US=>	MlHLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
TE-9	NWrGbpZFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mk\zTWM2OD1yLki3OVMzKM7:TR?=	NV;ENXN3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
A3-KAW	MoDkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mmi0TWM2OD1yLkm4OFUzKM7:TR?=	Mkf0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
A101D	NHT0c\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{LEb2lEPTB;MT6wN\|A1OyEQvF2=	Ml7SQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
OCUB-M	M4LrfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHW1bo5KSzVyPUGuNFQ1OTJizszN	NGLyeZQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
ES4	MkLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NY\IPYxKUUN3ME2xMlA2OTR3IN88US=>	MnvUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
TE-6	NI\OcY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUTJR\|UxRTFwMkGyNlYh\|ryP	NFXT[mc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
D-502MG	M17G[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mle2TWM2OD1zLkKzN\|c3KM7:TR?=	NYXTN4JJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
KNS-42	NUf3UIlPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVTJR\|UxRTFwMkS0NVIh\|ryP	NXTtS2h[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
SNU-C2B	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoXhTWM2OD1zLkOwOVg6KM7:TR?=	M3XxZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
NCI-H1838	MkHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MU\JR\|UxRTFwM{C3N\|Mh\|ryP	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
NKM-1	NUnOXWdDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHruOJJKSzVyPUGuN\|A5PTlizszN	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
GI-1	M2G2WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYHtOXN7UUN3ME2xMlM3OjJizszN	NWWyN5k1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
NB5	M2DNWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFfEOI9KSzVyPUGuN\|k5OjdizszN	NIrYNIs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
CAS-1	NWLxWYkyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWLmTWhwUUN3ME2xMlQxQTl{IN88US=>	M4XVPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
HCE-T	Mnn0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXXJR\|UxRTFwNU[3NVQh\|ryP	NYPsW2tvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
SBC-1	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVnJR\|UxRTFwNUe5PFQh\|ryP	NWi5SGxDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
JiyoyeP-2003	M2HNdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEHuN4lKSzVyPUGuO\|M1PjZizszN	NXm3O2lvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
TE-5	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mlu4TWM2OD1zLke5NVM6KM7:TR?=	MnjOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
CAN	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4nPPGlEPTB;MT64NlI2OiEQvF2=	NYTXUlBKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
SK-UT-1	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3fY[mlEPTB;Mj6xOlY6OyEQvF2=	M37qSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
JVM-2	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NE[3O45KSzVyPUKuN\|YzQDRizszN	M3ztPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
LB771-HNC	NIf4O4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4Pyc2lEPTB;Mj61O\|U2OSEQvF2=	M1zoV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
NCCIT	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYPJR\|UxRTJwOE[2NVYh\|ryP	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
NCI-H2126	M4G3c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGjqPZlKSzVyPUKuPFc2PTJizszN	NG\uWVQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
Calu-6	NV7yToxsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M33yOGlEPTB;Mz6wOVc1OSEQvF2=	NGD1eJQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
SK-LMS-1	M1m4U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlLZTWM2OD1\|LkGxPFg3KM7:TR?=	MoTjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
ARH-77	NYnVfmlsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnrxTWM2OD1\|LkS2PVE2KM7:TR?=	Mk\QQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
NB17	NXn6SllzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEDU[YtKSzVyPUOuOlM5PDdizszN	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
A253	MnzYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYDJR\|UxRTNwN{OyOFYh\|ryP	NYKzSms{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
OPM-2	M3nNOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWXqWYZmUUN3ME20MlI4Pjh3IN88US=>	NGTjWII9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
MV-4-11	NVPzUlMzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXjJR\|UxRTRwM{[0OVQh\|ryP	M2TXUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
SR	M134SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUO5TFZzUUN3ME20MlQ6QTV2IN88US=>	NYS2OYp1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
KG-1	NV;ZbmtJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYDJR\|UxRTRwNkC4OFUh\|ryP	MoPKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
OCI-AML2	MlrNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXf6fpNzUUN3ME21Mlg3OTV2IN88US=>	MkXYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
D-247MG	NYDue4ZDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MofiTWM2OD14LkGyOVE6KM7:TR?=	NX7hRoZjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
DJM-1	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUTJR\|UxRTZwNEi1OVgh\|ryP	NHHybmU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
RPMI-6666	NHHJRYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1HwNWlEPTB;Nz6yO\|A3PyEQvF2=	NFzBZlE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
KARPAS-45	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEPI[INKSzVyPUeuOVE3PzFizszN	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
LP-1	NFu4SJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH;DVmlKSzVyPUeuOVQ4QDJizszN	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
RS4-11	NVrDeppHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnnPTWM2OD15Lk[1O\|g4KM7:TR?=	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
DU-4475	MmnDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoftTWM2OD16LkKxOlUzKM7:TR?=	M3XzOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
MONO-MAC-6	NInQS5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4POU2lEPTB;OD6yO\|A3PiEQvF2=	M{PUXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
NCI-SNU-16	MmC1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYnR[ZR7UUN3ME24MlU3OTJ6IN88US=>	MoH4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
SJSA-1	M4\nOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUXIOZJoUUN3ME24MlczQDB3IN88US=>	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
MMAC-SF	NH7ofY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4G2b2lEPTB;OD63PVMxPyEQvF2=	MnfJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
SK-NEP-1	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX7vdIR3UUN3ME24Mlg6OTV3IN88US=>	NFnxTYg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
J-RT3-T3-5	NYXJdHFrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVe0WVRiUUN3ME24Mlk3PTJ7IN88US=>	MnLQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
SKM-1	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIf0cmhKSzVyPUmuNFE4OzRizszN	NHTHWVA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
LB2241-RCC	NHnmN5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXfmbI9wUUN3ME25MlAzODF{IN88US=>	MnzhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
SIG-M5	NGXNZXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1rJVGlEPTB;OT6wNlQ6OyEQvF2=	M4jZelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
EVSA-T	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mmj3TWM2OD17LkK3O\|k{KM7:TR?=	M{\3cVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
GT3TKB	NYLidIxNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXzJR\|UxRTlwM{W1OFYh\|ryP	NUP2T\|RiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
NB6	NIDnfFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUDyXZlYUUN3ME25MlkzOjV7IN88US=>	NF7WR249[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
EHEB	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFe0XJNKSzVyPUGwMlA3PTZizszN	NXTBZ4RqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
HEL	M2TBOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFe0OpBKSzVyPUGwMlQ4PzZizszN	MnnOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
ALL-PO	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWTJR\|UxRTFyLke5N\|gh\|ryP	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
TGW	NVvQUWhNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUfTRohXUUN3ME2xNU4zQDJ6IN88US=>	NWHEWZhiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
BC-3	MkXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXfhNohSUUN3ME2xNk4yOTN6IN88US=>	Mn3aQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
IA-LM	NGj5V\|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVnJR\|UxRTF{LkS0OFUh\|ryP	M{PhblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
UACC-257	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{fGOmlEPTB;MUKuPVE6QCEQvF2=	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
KP-N-YS	M3PpV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NG\WbZRKSzVyPUGyMlkzQDNizszN	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
Raji	NF3jVYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWTJR\|UxRTF\|Lke0PVch\|ryP	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
SF539	NFPYO3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnjZTWM2OD1zMz64OVU4KM7:TR?=	NGLudW09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
DMS-153	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEXCPGpKSzVyPUG0MlAxOjhizszN	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
L-540	M1Gzbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3H0T2lEPTB;MUWuNFY4OiEQvF2=	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
MN-60	NYXsSXM1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV34NGhUUUN3ME2xOU4yQTd7IN88US=>	Mmf0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
RPMI-8866	M2fDeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmjhTWM2OD1zNz60OFU1KM7:TR?=	MmTBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
NCI-H510A	MmPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXfJR\|UxRTF7LkO5O\|Mh\|ryP	NGK5dnU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
NB13	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NI[3NWZKSzVyPUG5MlQ5PzdizszN	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
HAL-01	NUOwcVFyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVfJR\|UxRTF7Lke1OFMh\|ryP	NYTJdGl7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
NCI-H720	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3T1[2lEPTB;MkCuNlc{OyEQvF2=	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
REH	M1nFOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHL4WGFKSzVyPUKwMlY{PTdizszN	M3W4S\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
KNS-81-FD	NF7uRYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlnCTWM2OD1{Mz6xOFYh\|ryP	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
HC-1	M37CZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV7uNZhkUUN3ME2yOE42PTVzIN88US=>	NHrEXY49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
NCI-H2141	NV[5fo1ET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX75T4Z7UUN3ME2yOE44PzV2IN88US=>	M4H1XVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
MOLT-4	MmPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH[xNJBKSzVyPUK2MlY4PTNizszN	NH7YbIQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
OMC-1	MoHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXfW[YZMUUN3ME2yO{4yPDJ{IN88US=>	MnPPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
LC-1F	MkPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYiySW5pUUN3ME2yO{4{OjR3IN88US=>	NVr3b\|B[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
NCI-H1304	M1;Vemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYr2c41CUUN3ME2yPE4yPjJ6IN88US=>	NEnhPIc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
BC-1	Mn3SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYDJR\|UxRTJ6Lk[1NUDPxE1?	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
NCI-H64	NWfaR2xQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NI\nOXVKSzVyPUK5MlYzPTNizszN	MkDHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
MOLT-16	M4HNXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIf6R5FKSzVyPUK5MlYzQTJizszN	NGfwdJI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
U-87-MG	M2\ETGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXvNeVBRUUN3ME2zNE44PjZizszN	M2r3UlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
GAK	NVXqNodNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVnJR\|UxRTNzLkK2PFYh\|ryP	M4HLe\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
ES8	NUjIWXdxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVnJR\|UxRTN{LkGyOVIh\|ryP	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
HCC1599	M4HXWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHS3S5FKSzVyPUOyMlM{OjVizszN	NH[wWHY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
EB-3	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2jONmlEPTB;M{SuN\|EyPyEQvF2=	MkLoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
HCC1187	M13TNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXW2fWVpUUN3ME2zOU45ODV{IN88US=>	NHnFS5Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
SK-PN-DW	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX;JR\|UxRTN4LkG5OFMh\|ryP	NUexVZYzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
JVM-3	MmTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NI\hV21KSzVyPUO3MlI{OzhizszN	MmHKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
HCC2157	NGG2cHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVv0No5kUUN3ME2zO{46QTR4IN88US=>	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
A4-Fuk	NX;3VVlsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYS0OZlGUUN3ME2zPE4yODB7IN88US=>	NF\JWoM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
COR-L279	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYCwVoV2UUN3ME20NE4zQDVzIN88US=>	M1GyRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
DEL	NIjuNlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWTJR\|UxRTRzLkmwPFYh\|ryP	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
NCI-H1395	M3r1Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWPJR\|UxRTR{LkCxOlMh\|ryP	NGrhVZI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
MHH-NB-11	NXLkSnJbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVnJR\|UxRTR\|LkC4NVgh\|ryP	MlXtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
NCI-H2107	M4[yU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWHJR\|UxRTR\|LkS4OFYh\|ryP	M2PGb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
NEC8	MkPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3W3S2lEPTB;NESuN\|M3KM7:TR?=	NHLwSWg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
COLO-684	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWXJR\|UxRTR4LkKyOVgh\|ryP	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
LS-411N	MnrtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEfXcmRKSzVyPUS4MlQ4PDhizszN	NX3rVo9GRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	phospho-c-Abl(Tyr245) / phospho-c-Src(Tyr416); PubMed: 23049975 PLoS One Protein levels of phosphorylated c-Abl (Tyr245), c-Abl, phosphorylated c-Src (Tyr416), c-Src, and GAPDH in NSC-34 cells overexpressing human wild-type or mutant SOD1s treated with various concentrations of dasatinib were measured by western blot. Cells were cultured in serum-free culture medium with doxycycline (Dox, 2 µg/ml), and western blot was performed at 24 h after dasatinib addition. p27 / p21; PubMed: 20145167 Clin Cancer Res Dasatnib induced cell cycle arrest. Dasatinib induced growth arrest, shown as a cell cycle distribution graph in the lower panel, correlated with increased p27 and p21 levels. Western blotting for levels of p27 and p21 was performed on protein lysates of THP-1 cells treated for 48 hours with indicated doses of dasatinib or DMSO. Detection of actin served as control for comparable protein loading. p-FAK / p-STAT3; PubMed: 23721490 BMC Cancer The effect of dasatinib in cell signalling. Western blot analysis with phosphorylated Src, FAK, Stat3, Akt and MAPK in HCC cell lines after 24 hours treatment of dasatinib. The cell lines were arranged according to their IC50 to dasatinib. The top three were most sensitive, the bottom 3 were least sensitive. cleaved caspase 3; PubMed: 20145167 Clin Cancer Res Dasatinib induced apoptosis. Dasatinib causes apoptosis in Mo7e-KitD816H cells as detected by cleavage of caspase 3. Whole cell lysates were prepared after 24 hour treatment with dasatinib. Caspase 3 and cleaved capase 3 were analyzed by western blotting. Actin serves as loading control.	23049975 20145167 23721490
Growth inhibition assay	IC50; PubMed: 23721490 BMC Cancer 9 HCC cell lines were exposed to the dedicated concentrations of dasatinib for 72 hours, and IC50 was tested by MTS. Results represent the mean (± SD) of three experiments.	23721490
Immunofluorescence	SRC / Met; PubMed: 26517812 Oncotarget Immunocytochemistry of SRC and Met localization. Cellular localization of SRC and Met following treatment for 48 h with dasatinib, crizotinib or combination in A. LN-18 and B. U373 cells. Scale bar denotes 10 μm. Nuclei were visualized by DAPI while SRC and Met were labeled with a fluorescein and Texas-red conjugated secondary antibodies, respectively. F-actin / Actinin-4 / Paxillin; PubMed: 31053734 Nat Commun Conditionally immortalized differentiated podocytes treated for one-hour with 2 µM kinase inhibitor were stained for F-actin (phalloidin), α-actinin-4, paxillin, and nuclei (Hoechst 33342) to assess cytoskeletal and focal adhesion architecture (scale bars = 50 µm). Podocytes treated with dasatinib showed a marked decrease in cell-to-cell contacts, cell size and number of focal adhesions. α-tubulin; PubMed: 26517812 Oncotarget Combination of dasatinib and crizotinib impedes the formation of the α-tubulin-labeled mitotic spindle. LN-18 cells were treated with dasatinib 0.2 μM, crizotinib 4 μM or their combination for 48 h. Mitotic spindle were visualized using α-tubulin antibody conjugated to a fluorescein-labeled secondary antibody. Nuclei were stained by DAPI. The scale bar denotes 10 μm.	26517812 31053734
ELISA	TNF-α; PubMed: 17684099 Proc Natl Acad Sci U S A U937 cells were differentiated with vitamin D3, pretreated with the indicated concentrations of drugs for 1 h and stimulated with LPS for 6 h. TNF-α secretion was measured by ELISA. The graph shows the mean of two experiments done in duplicate. E-selectin; PubMed: 31110200 Sci Rep HAoECs were treated with DMSO, a dual FAK/Pyk2 inhibitor (PF-271, 2.5 μM), a Src inhibitor (Dasatinib, 1 μM), or a FAK inhibitor (PF-228, 10 μM) for 1 h prior to TNF-α (10 ng/ml, 6 h) stimulation. Expression levels of E-selectin was determined using ELISA (n = 3, ±SEM). VCAM-1; PubMed: 31110200 Sci Rep HAoECs were treated with DMSO, a dual FAK/Pyk2 inhibitor (PF-271, 2.5 μM), a Src inhibitor (Dasatinib, 1 μM), or a FAK inhibitor (PF-228, 10 μM) for 1 h prior to TNF-α (10 ng/ml, 6 h) stimulation. Expression levels of VCAM-1 was determined using ELISA (n = 3, ±SEM).	17684099 31110200

体内研究

Dasatinib 作用于LMP2A/MYC 双转基因小鼠，可逆转脾肿大。Dasatinib 作用于TgE小鼠抑制表达LMP2A 的骨髓B 细胞形成的菌落，且使脾脏变小。使用Dasatinib处理Tg6/λ-MYC 小鼠，与对照组相比，脾脏质量明显降低。Dasatinib 作用于LMP2A/MYC 双转基因小鼠，抑制淋巴结肿大。Dasatinib作用于嫁接LMP2A/MYC双转基因小鼠肿瘤细胞的Rag1KO小鼠，可逆转脾肿大。Dasatinib 作用于表达LMP2A的B 淋巴细胞瘤，抑制Lyn磷酸化。^[2]

激酶实验：^[1]	- 合并激酶自磷酸化分析: 使用野生型和突变型谷胱甘肽S-转移酶(GST)-Abl融合蛋白 (c-Abl氨基酸220-498位) 进行激酶实验。从谷胱甘肽琼脂糖珠中释放GST-Abl融合蛋白，ATP浓度为5 μM。在用于激酶自磷酸化和体外肽底物磷酸化实验前, 用LAR酪氨酸磷酸酶处理GST-Abl 激酶域融合蛋白。在 30^oC下温育1小时后,加入1 mM 钒酸钠，激活LAR磷酸酶。进行免疫印迹分析，比较未处理的GST-Abl激酶和去磷酸化的GST-Abl激酶，使用磷酸化的特点抗体4G10来确认酪氨酸残基完全去磷酸化(>95%)，使用c-Abl抗体 CST 2862 来确认GST-Abl激酶的平衡负载。实验测定IC50值时所用Dasatinib浓度为0 nM到32 nM。Dasatinib作用于突变型T315I时浓度达到 1,000 nM。在体外肽底物磷酸化实验中使用相同抑制剂浓度。作用于GST-Src激酶和 GST-Lyn激酶的三种抑制剂的浓度范围相同。
细胞实验： ^[1]	- 合并 Cell lines: Ba/F3细胞系 Concentrations: 0 nM-32 nM Incubation Time: 72小时 Method: Ba/F3 细胞系重复培养三份，然后与浓度逐渐升高的 Dasatinib 温育72小时。通过MTS活性实验测定细胞增殖。IC50值和IC90值取自三组独立实验的平均值。Dasatinib作用的IC50值和IC90值为0 nM 到32 nM 。Dasatinib 作用于突变型T315I时所需浓度达到200 nM。 (Only for Reference)
动物实验：^[2]	- 合并 Animal Models: EμLMP2A(TgE 和Tg6品种),MYC (λ-MYC), 和LMP2A/λ-MYC双转基因小鼠(Tg6/λ-MYC) Dosages: 30 mg/kg Administration: 腹腔注射 (Only for Reference)

参考文献

[4] Dargart JL, et al. Antiviral Res. 2012, 95(1), 49-56.

- 合并

溶解度 (25°C)

体外	DMSO	98 mg/mL (200.81 mM)
	Water	Insoluble
	Ethanol	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 4% DMSO+30% PEG 300+5% Tween 80+ddH2O	5mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Dasatinib SDF

分子量	488.01
化学式	C₂₂H₂₆ClN₇O₂S
CAS号	302962-49-8
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	BMS-354825

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

研究领域

产品类型

定制您的化合物库